Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Острый лимфобластный лейкоз

Список литературы

  1. Pui C.-H. Treatment of acute leukemias. New directions for clinical research. New Jersey, Humana Press Inc., 2003.
  2. Rabin K.R., Gramatges M.M., Margolin J.F. Acute lymphoblastic leukemia // Principles and Practice of Pediatric Oncology, 7th ed. 2015. P. 463–497.
  3. Мякова Н.В. Острый лимфобластный лейкоз. // Практическое руководство по детским болезням. Под ред. Коколиной В.Ф., Румянцева А.Г., Том IV – Гематология/онкология детского возраста. Под ред. Румянцева А.Г., Самочатовой Е.В. М, Медпрактика-М, 2004, стр. 518–537.
  4. Карачунский А.И., Мякова Н.В. Острый лимфобластный лейкоз // Педиатрия: национальное руководство в 2 т. М, ГЭОТАР-Медиа, 2009, стр. 944–955.
  5. Hunger S.P., Mullighan C.G. Acute lymphoblastic leukemia in children // New England Journal of Medicine 2015; Vol. 373, № 16. P. 1541–1552.
  6. Cooper S.L., Brown P.A. Treatment of pediatric acute lymphoblastic leukemia // Pediatric Clinics of North America 2015; Vol. 62, № 1. P. 61–73.
  7. Swerdlow S.H. et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: International Agency for Research in Cancer (IARC) / ed. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H.T.J. 2017. 585 p.
  8. Alaggio R., Amador C., Anagnostopoulos I., et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms // Leukemia. 2022. Vol. 36, № 7. P. 1720–1748.
  9. Gökbuget N. et al. Recommendations of the European Working Group for Adult ALL (EWALL) // UNI-MED Verlag AG. 2011. 204 p.
  10. Kroeze E., Loeffen J.L.C., Poort V.M., Meijerink J.P.P. T-cell lymphoblastic lymphoma and leukemia: different diseases from a common premalignant progenitor? // Blood Advances 2020; Vol. 4, № 14. P. 3466‒3473.
  11. Knez V., Bao L., Carstens B., Liang X. Analysis of clinicopathological and cytogenetic differences between B-lymphoblastic lymphoma and B-lymphoblastic leukemia in childhood // Leukemia & Lymphoma 2020; Vol. 61, № 9. P. 2129‒2135.
  12. Alexander T.B., Orgel E. Mixed Phenotype Acute Leukemia: Current Approaches to Diagnosis and Treatment // Current Oncology Reports 2021; Vol. 23, № 2. P. 22.
  13. Weinberg O.K., Arber D.A., Döhner H., et al.. The International Consensus Classification of acute leukemias of ambiguous lineage // Blood 2023; Vol. 141, № 18. P. 2275‒2277.
  14. Дёмина И.А., Михайлова Е.В., Семченкова А.А., и др. Иммунофенотипирование в диагностике острых лейкозов неоднозначной линейности. Результаты централизованной диагностики и практические рекомендации // Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2024; Том 23, № 1. стр. 219‒230.
  15. Lee H.G., Baek H.J., Kim H.S., et al. Biphenotypic acute leukemia or acute leukemia of ambiguous lineage in childhood: clinical characteristics and outcome // Blood Research 2019; Vol. 54, № 1. P. 63‒73.
  16. Румянцев А.Г. Клинические рекомендации. Детская гематология. Под ред. Румянцева А.Г., Масчана А.А., Жуковской Е.В. М, ГЭОТАР-Медиа, 2015, 656 с.
  17. Temple W.C., Mueller S., Hermiston M.L., Burkhardt B. Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young adults // Best Practice & Research Clinical Haematology 2023; Vol. 36, № 1. P. 101449.
  18. Burkhardt B., Hermiston M.L. Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities // British Journal of Haematology 2019; Vol. 185, № 6. P. 1158‒1170.
  19. Hrusak O., de Haas V., Stancikova J., et al. International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia // Blood 2018; Vol. 132, № 3. P. 264‒276.
  20. Maruffi M., Sposto R., Oberley M.J., et al. Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis // Leukemia 2018; Vol. 32, №7. P. 1515‒1528.
  21. Heerema-McKenney A., Cleary M., Arber D. Pathology and molecular diagnosis of leukemias and lymphomas // Principles and Practice of Pediatric Oncology. 7th ed. Philadelphia, Pa: Lippincott Williams and Wilkins. 2015. P. 113–130.
  22. Wenzinger C., Williams E., Gru A.A. Updates in the pathology of precursor lymphoid neoplasms in the Revised Fourth edition of the WHO Classification of tumors of hematopoietic and lymphoid tissues // Current Hematologic Malignancy Reports 2018; Vol. 13, №4. P. 275–288.
  23. Wang S., He G. 2016 Revision to the WHO classification of acute lymphoblastic leukemia // Journal of Translational Internal Medicine 2017; Vol. 4, № 4. P. 147–149.
  24. George B.S., Yohannan B., Gonzalez A., Rios A. Mixed-Phenotype Acute Leukemia: Clinical Diagnosis and Therapeutic Strategies // Biomedicines 2022; Vol. 10, № 8. P. 1974.
  25. Khoury J.D., Solary E., Abla O., et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms // Leukemia 2022; Vol. 36, № 7. P. 1703‒1719.
  26. Румянцев А.Г. Эволюция лечения острого лимфобластного лейкоза у детей: эмпирические, биологические и организационные аспекты // Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2015; Том 14, № 1. стр. 5–15.
  27. Bassan R., Maino E., Cortelazzo S. Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment // European Journal of Haematology 2016; Vol. 96, № 5. P. 447‒460.
  28. Cortelazzo S., Ferreri A., Hoelzer D., Ponzoni M. Lymphoblastic lymphoma // Critical Reviews in Oncology/Hematology 2017; Vol. 113. P. 304‒317.
  29. Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®) – Health Professional Version ‒ NCI [Electronic resource]. URL: https://www.cancer.gov/types/leukemia/hp/child-all-treatment-pdq (accessed: 27.05.2024).
  30. Childhood Non-Hodgkin Lymphoma Treatment (PDQ®) – Health Professional Version ‒ NCI [Electronic resource]. URL: https://www.cancer.gov/types/lymphoma/hp/child-nhl-treatment-pdq#_322 (accessed: 27.05.2024).
  31. Weinberg O.K., Arber D.A. How I Diagnose Acute Leukemia of Ambiguous Lineage // American Journal of Clinical Pathology 2022; Vol. 158, № 1. P. 27‒34.
  32. Bene M.C. et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). // Leukemia. 1995. Vol. 9, № 10. P. 1783–1786.
  33. Coustan-Smith E. et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia // Lancet Oncol. 2009. Vol. 10, № 2. P. 147–156.
  34. Dworzak M.N. et al. AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia // Cytometry B Clin Cytom. John Wiley and Sons Inc., 2018. Vol. 94, № 1. P. 82–93.
  35. Попов А.М. et al. Диагностическое иммунофенотипирование острых лейкозов. Рекомендации российско-белорусской кооперативной группы по диагностике острых лейкозов // Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2023. Том 22, № 1. стр. 165–177.
  36. Vardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes // Blood 2009; Vol. 114, № 5. P. 937‒951.
  37. Arber D.A., Orazi A., Hasserjian R., et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia // Blood 2016; VOL. 127, № 20. P. 2391‒2405.
  38. Alexander T.B., Gu Z., Iacobucci I., et al. The genetic basis and cell of origin of mixed phenotype acute leukaemia // Nature 2018; Vol. 562, № 7727. P. 373‒379.
  39. Demina I., Zerkalenkova E., Semchenkova A., et al. Rare case of pediatric trilineal mixed-phenotype acute leukemia with t(11;19)(q23.3;p13)/KMT2A::ELL Leukemia Research 2023; Vol. 125. P. 107018.
  40. Kotrova M., Musilova A., Stuchly J., te al. Distinct bilineal leukemia immunophenotypes are not genetically determined // Blood 2016; Vol. 128, № 18. P. 2263‒2266.
  41. Румянцев А.Г., Масчан А.А., Самочатова Е.В. Сопроводительная терапия и контроль инфекций при гематологических и онкологических заболеваниях. Москва: МЕДПРАКТИКА-М, 2009, 448 с.
  42. Масчан М.А., Мякова Н.В. Острый лимфобластный лейкоз у детей // Вместе против рака 2006; Том 1–2. стр. 50–63.
  43. Литвинов Д.В., Карелин А.Ф., Романова К.И., и др. Лечение острого лимфобластного лейкоза у детей: современные возможности и нерешенные проблемы // Доктор.Ру 2015; Том 10, № 111. стр. 30–37.
  44. Pui C.H. Toward a total cure for acute lymphoblastic leukemia // Journal of Clinical Oncology 2009; Vol. 27, № 31. P. 5121–5123.
  45. Vrooman L.M., Silverman L.B. Childhood acute lymphoblastic leukemia: Update on prognostic factors // Current Opinion in Pediatrics 2009; Vol. 21, № 1. P. 1–8.
  46. Hunger S.P., Baruchel A., Biondi A., et al. The thirteenth international childhood acute lymphoblastic leukemia workshop report: La Jolla, CA, USA, December 7-9, 2011 // Pediatric Blood & Cancer 2013; Vol. 60, № 2. P. 344–348.
  47. Inaba H., Mullighan C.G. Pediatric acute lymphoblastic leukemia // Haematologica 2020; Vol. 105, № 11. P. 2524–2539.
  48. Kimura S., Mullighan C.G. Molecular markers in ALL: Clinical implications // Best Practice & Research Clinical Haematology 2020; Vol. 33, № 3. P. 101193.
  49. Pui C.-H. Precision medicine in acute lymphoblastic leukemia // Frontiers in Medicine 2020; Vol. 14, № 6. P. 689–700.
  50. Brown P., Inaba H., Annesley C., et al. Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology // Journal of the National Comprehensive Cancer Network 2020; Vol. 18, № 1. P. 81‒112.
  51. Aguirre-Guillén W.A., Angeles-Floriano T., López-Martínez B., et al. Omics techniques and biobanks to find new biomarkers for the early detection of acute lymphoblastic leukemia in middle-income countries: a perspective from Mexico // Boletín Médico del Hospital Infantil de México (English Edition) 2017; Vol. 74, № 3. P. 227‒232.
  52. Velasco P., Bautista F., Rubio A., et al. The relapsed acute lymphoblastic leukemia network (ReALLNet): a multidisciplinary project from the spanish society of pediatric hematology and oncology (SEHOP) // Frontiers in Pediatrics 2023; Vol. 11. P. 1269560.
  53. Lund B., Najmi L.A., Wesolowska-Andersen A., et al. Archival bone marrow samples: suitable for multiple biomarker analysis // Applied Immunohistochemistry & Molecular Morphology 2015; Vol. 23, № 1. P. 71‒77.
  54. Pui C.-H. Toward optimal central nervous system-directed treatment in childhood acute lymphoblastic leukemia // Journal of Clinical Oncology 2003; Vol. 21, № 2. P. 179–181.
  55. Bürger B., Zimmermann M., Mann G., et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: Significance of low leukocyte counts with blasts or traumatic lumbar puncture // Journal of Clinical Oncology 2003; Vol. 21, № 2. P. 184–188.
  56. Farrell K., Fyfe A., Allan J., et al. An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events // Leukemia & Lymphoma 2016; Vol. 57, № 11. P. 2568–2574.
  57. Greiner J., Schrappe M., Claviez A., et al. THROMBOTECT ‒ a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents // Haematologica 2019; Vol. 104, № 4. P. 756–765.
  58. Seregina E. et al. Laboratory Monitoring of Coagulation State in Children with Acute Lymphoblastic Leukemia // ISTH Congress. 2021. P. PB1099.
  59. Карачунский А.И., и др. ALL-MB 2015. Протокол кооперативной группы Москва-Берлин по исследованию острого лимфобластного лейкоза у детей. Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева. Версия 10.10.2015 [Electronic resource], 2015, 244 с. URL: http://www.fnkc.ru/docs/ALLMB2015.pdf.
  60. Greenmyer J.R., Wyatt K.D., Rodriguez V., et al. Management Practices for Asparaginase-associated Coagulopathy: A Survey of Pediatric Oncologists // Journal of Pediatric Hematology/Oncology 2022; Vol. 44, № 8. P. e1023‒e1028.
  61. George G., Rezazadeh A., Zook F., et al. Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase-A real world study // Leukemia Research 2020; Vol. 94. P. 106368.
  62. Cook J., Litzow M. Advances in Supportive Care for Acute Lymphoblastic Leukemia // Current Hematologic Malignancy Reports 2020; Vol. 15, № 4. P. 276‒293.
  63. Salvador C., Salvador R., Kropshofer G., et al. Prophylaxis with enoxaparin and antithrombin III in drug-induced coagulation alterations in childhood leukemia: a retrospective experience of 20 years // Thrombosis Journal 2024; Vol. 22, № 1. P. 30.
  64. Rodriguez V. Thrombosis Complications in Pediatric Acute Lymphoblastic Leukemia: Risk Factors, Management, and Prevention: Is There Any Role for Pharmacologic Prophylaxis? // Frontiers in Pediatrics 2022; Vol. 10. P. 828702.
  65. Lim W., Le Gal G., Bates S.M., et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism // Blood Advances 2018; Vol. 2, № 22. P. 3226‒3256.
  66. Евстратов Д.А., Жарков П.А., Дьяконова Ю.Ю., и др. Тромбоз венозных синусов головного мозга и кровоизлияние в ткань головного мозга у пациента с лимфобластной лимфомой // Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2015; Том 14, № 2. стр. 43‒47.
  67. Шифрин Ю.А., Жарков П.А., Пашанов E.Д. Применение концентрата протеина С у детей с приобретенным его дефицитом // Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2019; Том 18, № 2. стр. 59‒65.
  68. Abdel-Azim N., Alkilany L.F., Hassan Z.K., Gaber N. Investigating causes and risk factors of pre-chemotherapy viremia in acute lymphoblastic leukemia pediatric patients // Infection 2023; Vol. 51, № 1. P. 203‒211.
  69. Kebudi R., Özdemir N. Changes in hepatitis B antibody status after chemotherapy in children with cancer // Pediatric Blood & Cancer 2020; Vol. 67, № 4. P. e28120.
  70. Tavil B., Cetin M., Tuncer M., et al. The rate of hepatitis B and C virus infections and the importance of HBV vaccination in children with acute lymphoblastic leukemia // Hepatology Research 2007; Vol. 37, № 7. P. 498‒502.
  71. Hausfater P., Cacoub P., Sterkers Y., et al. Hepatitis C virus infection and lymphoproliferative diseases: prospective study on 1,576 patients in France // American Journal of Hematology 2001; Vol. 67, № 3. P. 168‒171.
  72. Swilley S., Strickland D.K., Davila R., et al. Hepatitis C infection during treatment for childhood cancer: pitfalls in diagnosis and management // Medical and Pediatric Oncology 2002; Vol. 39, № 1. P. 58‒59.
  73. Варачек Н.М. Клинико-бактериологические аспекты нарушений микробиоценоза кишечника у детей с острым лимфобластным лейкозом. Диссертация на соискание ученой степени кандидата медицинских наук. Оренбург, 2010.
  74. Averbuch D., Orasch C., Cordonnier C., et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia // Haematologica 2013; Vol. 98, № 12. P. 1826‒1835.
  75. Nellis M.E., Goel R., Karam O. Transfusion Management in Pediatric Oncology Patients // Hematology/Oncology Clinics of North America. W.B. Saunders, 2019. Vol. 33, № 5. P. 903–913.
  76. Leahy M.F., Mukhtar S.A. From blood transfusion to patient blood management: a new paradigm for patient care and cost assessment of blood transfusion practice // Internal Medicine Journal 2012; Vol. 42, №3. P. 332‒338.
  77. Трахтман П.Е., Старостин Н.Н., Новичкова Г.А., Ворожцов И.Н. Трансфузионная терапия в клинической практике: учеб. пособие / Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Д. Рогачева. Москва, 2021, 76 с.
  78. Hoo C.P.L., Leung A.W.K., Chan J.P.K., et al. The incidence, risk factors, and outcomes of symptomatic avascular necrosis of bone among Chinese pediatric patients with acute lymphoblastic leukemia // Cancer Medicine 2023; Vol. 12, № 9. P. 10315‒10325.
  79. Biddeci G., Bosco G., Varotto E., et al. Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia: Early Diagnosis and New Treatment Strategies // Anticancer Research 2019; Vol. 39, № 3. P. 1259‒1266.
  80. Kunstreich M., Kummer S., Laws H.J., et al. Osteonecrosis in children with acute lymphoblastic leukemia // Haematologica 2016; Vol. 101, № 11. P. 1295‒1305.
  81. Riccio I., Pota E., Marcarelli M., et al. Osteonecrosis as a complication in pediatric patients with acute lymphoblastic leukemia // Pediatr Med Chir 2016; Vol. 38, № 3. P. 118.
  82. Schultz K.R., Pullen D.J., Sather H.N. et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: A combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG) // Blood 2007; Vol. 109, № 3. P. 926–935.
  83. Gaynon P.S., Desai A.A., Bostrom B.C. et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review // Cancer 1997; Vol. 80, № 9. P. 1717–1726.
  84. Gao J., Liu W.J. Prognostic value of the response to prednisone for children with acute lymphoblastic leukemia: A meta-analysis // European Review for Medical and Pharmacological Sciences 2018; Vol. 22, № 22. P. 7858–7866.
  85. Leoni V., Biondi A. Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia // Haematologica 2015; Vol. 100, № 3. P. 295.
  86. Bernt K.M., Hunger S.P. Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia // Frontiers in Oncology 2014; Vol. 25, № 4. P. 54.
  87. Soverini S., Bassan R., Lion T. Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: Recent advances and remaining challenges // Journal of Hematology and Oncology 2019; Vol. 12, № 1. P. 1–14.
  88. Arunachalam A.K., Janet N.B., Korula A., et al. Prognostic value of MRD monitoring based on BCR-ABL1 copy numbers in Philadelphia chromosome positive acute lymphoblastic leukemia // Leukemia & Lymphoma 2020; Vol. 61, № 14. P. 3468–3475.
  89. van der Sluis I.M., Vrooman L.M., Pieters R., et al. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation // Haematologica 2016; Vol. 101, № 3. P. 279‒285.
  90. Tsurusawa M., Chin M., Iwai A., et al.  L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment // Cancer Chemotherapy and Pharmacology. 2004; Vol. 53, № 3. P. 204‒208
  91. Boos J., Werber G., Ahlke E., et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations // European Journal of Cancer 1996; Vol. 32A, № 9. P. 1544‒1550.
  92. Asselin B., Rizzari C. Asparaginase pharmacokinetics and implications of therapeutic drug monitoring // Leukemia & Lymphoma 2015; Vol. 56, № 8. P. 2273–2280.
  93. Cooper S.L., Young D.J., Bowen C.J. et al. Universal premedication and therapeutic drug monitoring for asparaginase-based therapy pre vents infusion-associated acute adverse events and drug substitutions // Pediatric Blood & Cancer 2019; Vol. 66, № 8. P. e27797.
  94. Валиев Т.Т. Токсические эффекты препаратов L-аспарагиназы при лечении острого лимфобластного лейкоза // Онкогематология 2023; Том 18, № 3. стр. 134–139.
  95. Nadeem K., Colantonio D., Kircanski I., et al. Clinical decisions following implementation of asparaginase activity monitoring in pediatric patients with acute lymphoblastic leukemia: Experience from a single-center study // Pediatric Blood & Cancer 2020; Vol. 67, № 2. P. e28044.
  96. Lassaletta Á., Gutiérrez F.; PEGASO study investigators. Asparaginase activity monitoring in pediatric acute lymphoblastic leukemia: A cross-sectional nationwide study in Spain // Cancer reports (Hoboken, N.J.) 2023; Vol. 6, № 2. P. e1729.
  97. Coe-Eisenberg T.D., Perissinotti A.J., Marini B.L., et al. Evaluating the efficacy and toxicity of dose adjusted pegylated L-asparaginase in combination with therapeutic drug monitoring // Annals of Hematology 2023; Vol. 102, № 11. P. 3133‒3141.
  98. Czogala M., Rogatko I., Pawińska-Wąsikowska K., et al. Monitoring of treatment with L-asparaginase in children with acute lymphoblastic leukaemia, with a focus on silent inactivation and its influence on the treatment outcome // Contemporary Oncology (Pozn) 2022; Vol. 26, № 4. P. 282‒288.
  99. Lanvers C., Vieira Pinheiro J.P., Hempel G., et al. Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum // Analytical Biochemistry 2002; Vol. 309, № 1. P. 117‒126.
  100. Осипьянц А.И., Шикалов А.Б., Тумутолова О.М. и др. Модификация и валидация лабораторного метода определения активности L-аспарагиназы в сыворотке крови пациентов // Химико-фармацевтический журнал 2023; Том 57, № 2. стр. 58-60.
  101. Wang N., Ji W., Wang L., et al. Overview of the structure, side effects, and activity assays of l-asparaginase as a therapy drug of acute lymphoblastic leukemia // RSC Medicinal Chemistry journal 2022; Vol. 13, № 2. P. 117‒128.
  102. Song Z., Hu Y., Liu S., et al. Medication therapy of high-dose methotrexate: An evidence-based practice guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society // British Journal of Clinical Pharmacology 2022; Vol. 88, № 5. P. 2456‒2472.
  103. Howard S.C., McCormick J., Pui C.H., et al. Preventing and Managing Toxicities of High-Dose Methotrexate // Oncologist 2016; Vol. 21, № 12. P. 1471‒1482.
  104. Диникина Ю.В., Смирнова А.Ю., Голубева К.М., и др. Применение высоких доз метотрексата у детей с онкологическими заболеваниями: особенности сопроводительной терапии, оценка токсичности // Российский журнал детской гематологии и онкологии (РЖДГиО) 2018; Том 5, № 2. стр. 11‒18.
  105. Евсютина Е.П., Диникина Ю.В., Белогурова М.Б., Александрович Ю.С. Профилактика токсичности при химиотерапии высокими дозами метотрексата у детей // Педиатр 2019; Том 10, № 2. стр. 89‒98.
  106. Громова Е.Г., Бирюкова Л.С., Джумабаева Б.Т., Курмуков И.А. Практические рекомендации по коррекции нефротоксичности противоопухолевых препаратов // Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2019 (том 9). стр. 655–667.
  107. Borowitz M.J., Devidas M., Hunger S.P., et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children’s Oncology Group study // Blood 2008; Vol. 111, № 12. P. 5477–5485.
  108. Conter V., Bartram C.R., Valsecchi M.G., et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFMALL 2000 study // Blood 2010; Vol. 115, № 16. P. 3206–3214.
  109. Schrappe M., Valsecchi M.G., Bartram C.R., et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: Results of the AIEOP-BFM-ALL 2000 study // Blood 2011; Vol. 118, № 8. P. 2077–2084.
  110. Попов А.М., Михайлова Е.В., Вержбицкая Т.Ю., и др. Определение минимальной остаточной болезни при В-линейном остром лимфобластном лейкозе методом проточной цитометрии. Рекомендации российскобелорусской кооперативной группы по диагностике острых лейкозов у детей // Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2023; Том 22, № 3. стр. 199–209.
  111. Sramkova L., Muzikova K., Fronkova E., et al. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia // Pediatric Blood & Cancer 2007; Vol. 48, № 1. P. 93–100.
  112. Shen Z., Gu X., Mao W., et al. Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis // BMC Cancer 2018; Vol. 18, № 1. P. 755.
  113. Sanchez-Garcia J., Serrano J., Serrano-Lopez J., et al. Quantification of minimal residual disease levels by flow cytometry at time of transplant predicts outcome after myeloablative allogeneic transplantation in ALL // Bone Marrow Transplant 2013; Vol. 48, № 3. P. 396–402.
  114. Nguyen H.T.K., Terao M.A., Green D.M., et al. Testicular involvement of acute lymphoblastic leukemia in children and adolescents: Diagnosis, biology, and management // Cancer 2021; Vol. 127, № 17. P. 3067–3081.
  115. Bhojwani D., Pui C.H. Relapsed childhood acute lymphoblastic leukaemia // The Lancet Oncology 2013; Vol. 14, № 6. P. e205–e217.
  116. Roberts A.S., Shetty A.S., Mellnick V.M., et al. Extramedullary haematopoiesis: radiological imaging features // Clinical Radiology 2016; Vol. 71, № 9. P. 807–814.
  117. Herrmann J., Lerman A., Sandhu N.P., et al. Evaluation and management of patients with heart disease and cancer: cardio-oncology // Mayo Clinic Proceedings 2014; Vol. 89, № 9. P. 1287–1306.
  118. Armenian S., Bhatia S. Predicting and Preventing Anthracycline-Related Cardiotoxicity // American Society of Clinical Oncology Educational Book 2018; Vol. 38. P. 3–12.
  119. Podpeskar A., Crazzolara R., Kropshofer G., et al. Supportive methods for childhood acute lymphoblastic leukemia then and now: A compilation for clinical practice // Frontiers in Pediatrics 2022; Vol. 10. P. 980234.
  120. Soylu A.R., Buyukasik Y., Cetiner D., et al. Overt gastrointestinal bleeding in haematologic neoplasms // Digestive and Liver Disease 2005; Vol. 37, № 12. P. 917–922.
  121. Hummel M., Rudert S., Hof H., et al. Diagnostic yield of bronchoscopy with bronchoalveolar lavage in febrile patients with hematologic malignancies and pulmonary infiltrates // Annals of Hematology 2008; Vol. 87, № 4. P. 291–297.
  122. Fox T.A., Carpenter B., Taj M., et al. Utility of 18F-FDG-PET/CT in lymphoblastic lymphoma // Leukemia & Lymphoma 2021; Vol. 62, № 4. P. 1010–1012.
  123. Kroeze E., Padilla L.A., Burkhardt B., et al. 18 F-FDG-PET/CT imaging in diagnostic workup of pediatric precursor B-cell lymphoblastic lymphoma // Pediatric Blood & Cancer 2023; Vol. 70, № 11. P. e30642
  124. Sengar M., Jain H., Menon H., et al. Whole body PET-CT in management of lymphoblastic lymphomas in adults: Does it have a prognostic impact? // Blood 2013; Vol. 122, № 21. P. 4314
  125. Śliwa-Tytko P., Kaczmarska A., Lejman M., Zawitkowska J. Neurotoxicity Associated with Treatment of Acute Lymphoblastic Leukemia Chemotherapy and Immunotherapy // International Journal of Molecular Sciences 2022; Vol. 23, № 10. P. 5515.
  126. Li R., Tang J.H., Zhang B.B., et al. Clinical Analysis of Childhood Acute Lymphoblastic Leukemia With Epilepsy Seizures // Frontiers in Neurologyl 2022; Vol. 13. P. 824268.
  127. Dhariwal N., Roy Moulik N., Smriti V., et al. Clinico-radiological profile, management and follow-up of methotrexate induced neurotoxicity in children with acute lymphoblastic leukemia. Leukemia & Lymphoma 2023; Vol. 64, № 12. P. 1971–1980.
  128. Baytan B., Evim M.S., Güler S., et al. Acute Central Nervous System Complications in Pediatric Acute Lymphoblastic Leukemia // Pediatric Neurology 2015; Vol. 53, №4. P. 312–318.
  129. Жарков П.А., Грачева М.А., Ройтман Е.В., и др. Распространенность тромбозов глубоких вен у детей с онкогематологической патологией // Тромбоз, гемостаз и реология 2015, Том 63, №3. стр. 29–34.
  130. Levy-Mendelovich S., Barg A.A., Kenet G. Thrombosis in pediatric patients with leukemia // Thrombosis Research 2018; Vol. 164 (Suppl 1). P. S94–S97.
  131. Jones S., Monagle P., Newall F. Do asymptomatic clots in children matter? // Thrombosis Research 2020; Vol. 189, P. 24–34.
  132. Федорова Д.В., Жарков П.А., Пшонкин А.В. Тромботические наложения на центральных венозных катетерах как фактор риска развития катетер-ассоциированных тромбозов глубоких вен // Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2016; Том 15, №2. стр. 20–26
  133. Жарков П.A., Морозова Д.С., Гобадзе Д.A., и др. Тромбозы глубоких вен у детей с заболеваниями крови // Онкогематология 2019; Том 14, № 1. стр. 20–30
  134. Schmiegelow K., Attarbaschi A., Barzilai S., et al. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus // The Lancet Oncology 2016; Vol. 17, № 6. P. e231–e239.
  135. Schmiegelow K., Müller K., Mogensen S.S., et al. Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy // F1000Research 2017; Vol. 6. P. 444.
  136. Румянцев А.Г. Эволюция лечения острого лимфобластного лейкоза у детей // Педиатрия 2016; Том 95, № 4. стр. 11–22.
  137. Румянцева Ю.В., Карачунский А.И., Румянцев А.Г. Оптимизация терапии острого лимфобластного лейкоза у детей в России // Педиатрия 2009; Том 87, № 4. стр. 19–28.
  138. Ribera JM. Allogeneic stem cell transplantation for adult acute lymphoblastic leukemia: when and how // Haematologica 2011; Vol. 96, № 8. P. 1083–1086.
  139. Merli P., Algeri M., Del Bufalo F., Locatelli F. Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia // Current Hematologic Malignancy Reports 2019; Vol. 14, № 2. P. 94–105.
  140. Balduzzi A., Valsecchi M.G., Uderzo C., et al. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: Comparison by genetic randomisation in an international prospective study // Lancet 2005; Vol. 366, № 9486. P. 635–642.
  141. Schrauder A., Reiter A., Gadner H., et al. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: Results from ALL-BFM 90 and 95 // Journal of Clinical Oncology 2006; Vol. 24, № 36. P. 5742–5749.
  142. Ribera J.M., Ortega J.J., Oriol A., et al. Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 trial // Journal of Clinical Oncology 2007; Vol. 25, № 1. P. 16–24.
  143. Duval M., Klein J.P., He W., et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure // Journal of Clinical Oncology 2010; Vol. 28, № 23. P. 3730–3738.
  144. Адамян Л.В., Сибирская Е.В., Пивазян Л.Г., и др. Методы сохранения фертильности у онкологических больных в детском возрасте // Опухоли женской репродуктивной системы 2023; Том 19, № 4. стр. 123–131.
  145. Close A., Burns K., Bjornard K., et al. Fertility preservation in pediatric leukemia and lymphoma: A report from the Children's Oncology Group // Pediatric Blood & Cancer 2023; Vol. 70, № 8. P. e30407.
  146. Oktay K., Harvey B.E., Partridge A.H., et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update // Journal of Clinical Oncology 2018; Vol. 36, № 19. P. 1994–2001.
  147. Brungardt J.G., Burns K.C., Dasgupta R. Fertility preservation in children and young adults with cancer // Current Opinion in Pediatrics 2022; Vol. 34, № 1. P. 48–52.
  148. Lehrnbecher T., Robinson P., Fisher B., et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update // Journal of Clinical Oncology 2017; Vol. 35, № 18. P. 2082–2094.
  149. Groll A.H., Pana D., Lanternier F., et al. 8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation // The Lancet Oncology 2021; Vol. 22, № 6. P. e254–e269.
  150. Biswal S., Godnaik C. Incidence and management of infections in patients with acute leukemia following chemotherapy in general wards // Ecancermedicalscience 2013; Vol. 7. P. 310.
  151. Inaba H., Pei D., Wolf J., et al. Infection-related complications during treatment for childhood acute lymphoblastic leukemia // Annals of Oncology 2017; Vol. 28, № 2. P. 386–392.
  152. Boeriu E., Borda A., Vulcanescu D.D., et al. Diagnosis and Management of Febrile Neutropenia in Pediatric Oncology Patients-A Systematic Review // Diagnostics (Basel) 2022; Vol. 12, № 8. P. 1800.
  153. Bochennek K., Luckowitsch M., Lehrnbecher T. Recent advances and future directions in the management of the immunocompromised host // Seminars in Oncology 2020; Vol. 47, № 1. P. 40–47.
  154. Pui C.H. Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment // Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2006. P. 142–146.
  155. Румянцева Ю.В., Пономарева Н.И., Фечина Л.Г., и др. Профилактика нейролейкемии у детей с острым лимфобластным лейкозом: стратегия Москва-Берлин // Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2009; Том 8, №2. стр. 5–14.
  156. Pui C.H., Evans W.E. A 50-year journey to cure childhood acute lymphoblastic leukemia // Seminars in Hematology 2013; Vol. 50, № 3. P. 185–196.
  157. Karachunskiy A., Herold R., von Stackelberg A., et al. Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia // Leukemia 2008; Vol. 22, № 6. P. 1144–1153.
  158. Румянцева Ю.В., Карачунский А.И., Алейникова О.В., et al. Эффективность протокола ALL-МВ-2002 у детей с острым лимфобластным лейкозом // Терапевтический архив 2010; Том 82, № 7. стр. 11–20.
  159. Karachunskiy A., Roumiantseva J., Lagoiko S., et al. Efficacy and toxicity of dexamethasone vs methylprednisolone - Long-term results in more than 1000 patients from the Russian randomized multicentric trial ALL-MB 2002 // Leukemia 2015; Vol. 29, № 9. P. 1955–1958.
  160. Möricke A., Zimmermann M., Reiter A., et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000 // Leukemia 2010; Vol. 24, № 2. P. 265–284.
  161. Фукс О.Ю., Кондратчик К.Л., Мякова Н.В., et al. Ранний ответ на терапию при использовании ПЭГ-аспарагиназы в циторедуктивной фазе лечения острого лимфобластного лейкоза // Гематология и траснфузиология 2007; Том 52, № 6. стр. 22–26.
  162. Kumar K., Kaur J., Walia S., et al. L-asparaginase: An effective agent in the treatment of acute lymphoblastic leukemia // Leukemia & Lymphoma 2014; Vol. 55, № 2. P. 256–262.
  163. Schrappe M., Hunger S.P., Pui C.H., et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia // New England Journal of Medicine 2012; Vol. 366, № 15. P. 1371–1381.
  164. Pui C.-H., Howard S.C. Current management and challenges of malignant disease in the CNS in paediatric leukaemia // The Lancet Oncology 2008; Vol. 9, № 3. P. 257–268.
  165. Pui C.H., Campana D., Pei D., et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation // New England Journal of Medicine 2009; Vol. 360, № 26. P. 2730–2741.
  166. Richards S., Pui C.H., Gayon P.; Childhood Acute Lymphoblastic Leukemia Collaborative Group (CALLCG). Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia // Pediatric Blood & Cancer 2013; Vol. 60, № 2. P. 185–195.
  167. Супрун Р.Н., Румянцева Ю.В., Быданов О.И., и др. Острый лимфобластный лейкоз у детей с синдромом Дауна: опыт группы «Москва–Берлин» // Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2021; Том 20, № 1. стр. 14–26.
  168. Schultz K.R., Bowman W.P., Aledo A. Continuous dosing Imatinib with intensive chemotherapy gives equivalent outcomes to allogeneic BMT for Philadelphia chromosome-positive (Phю) acute lymphoblastic leukemia (ALL) with longer term follow up: Updated Results of Children’s Oncology Group (COG) // Pediatric Blood & Cancer  2010; Vol. 54. P. 788.
  169. Schultz K.R., Carroll A., Heerema N.A., et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s oncology group study AALL0031 // Leukemia 2014; Vol. 28, № 7. P. 1467–1471.
  170. Short N.J., Kantarjian H., Jabbour E., et al. Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia? // Best Practice & Research Clinical Haematology 2017; Vol. 30, № 3. P. 193–200.
  171. Chen M., Zhu Y., Lin Y., et al. Use of tyrosine kinase inhibitors for paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia: a systematic review and meta-analysis // BMJ Open 2021; Vol. 11, № 1. P. e042814.
  172. Slayton W.B., Schultz K.R., Silverman L.B., et al. How we approach Philadelphia chromosome‐positive acute lymphoblastic leukemia in children and young adults // Pediatric Blood & Cancer 2020; Vol. 67, № 10. P. e28543.
  173. Ganguly S., Sasi A., Pushpam D., et al. Philadelphia Chromosome Positive and Philadelphia-Like Acute Lymphoblastic Leukemia in Children and Adolescents: Current Management, Controversies and Emerging Concepts // Indian Journal of Pediatrics 2024; Vol. 91, № 1. P. 37–46.
  174. Shen S., Chen X., Cai J., et al. Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia // JAMA Oncology 2020; Vol. 6, № 3. P. 358.
  175. Hunger S.P., Tran T.H., Saha V., et al. Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial // The Lancet Haematology 2023; Vol. 10, № 7. P. e510–e520.
  176. Cerchione C., Locatelli F., Martinelli G. Dasatinib in the Management of Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia // Frontiers in Oncology 2021; Vol. 11. P. 632231
  177. Slayton W.B., Schultz K.R., Kairalla J.A., et al. Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: Results of Children’s Oncology Group Trial AALL0622 // Journal of Clinical Oncology 2018; Vol. 36, № 22. P. 2306–2314.
  178. Porkka K., Koskenvesa P., Lundán T., et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system philadelphia chromosome positive leukemia // Blood 2008; Vol. 112, № 4. P. 1005–1012.
  179. Millot F., Suttorp M., Versluys A.B., et al. Ponatinib in childhood Philadelphia chromosome–positive leukaemias: an international registry of childhood chronic myeloid leukaemia study // European Journal of Cancer 2020; Vol. 136. P. 107–112.
  180. Kodama Y., Sato A., Kato K., et al. Ponatinib in pediatric patients with Philadelphia chromosome-positive leukemia: a retrospective survey of the Japan Children’s Cancer Group // International Journal of Hematology 2022; Vol. 116, № 1. P. 131–138.
  181. Rossoff J., Huynh V., Rau R.E., et al. Experience with ponatinib in paediatric patients with leukaemia // British Journal of Haematology 2020; Vol. 189, № 2. P. 363–368.
  182. Chiaretti S., Messina M., Foà R. BCR/ABL1–like acute lymphoblastic leukemia: How to diagnose and treat? // Cancer 2019; Vol. 125, № 2. P. 194–204.
  183. Khan M., Siddiqi R., Tran T.H. Philadelphia chromosome-like acute lymphoblastic leukemia: A review of the genetic basis, clinical features, and therapeutic options // Seminars in Hematology 2018; Vol. 55, № 4. P. 235–241.
  184. Roberts K.G. Why and how to treat Ph-like ALL? // Best Practice & Research Clinical Haematology 2018; Vol. 31, № 4. P. 351–356.
  185. Kotb A., El Fakih R., Hanbali A., et al. Philadelphia-like acute lymphoblastic leukemia: diagnostic dilemma and management perspectives // Experimental Hematology 2018; Vol. 67. P. 1–9.
  186. Pui C.H., Roberts K.G., Yang J.J., et al. Philadelphia Chromosome–like Acute Lymphoblastic Leukemia // Clinical Lymphoma, Myeloma and Leukemia 2017; Vol. 17, № 8. P. 464–470.
  187. Harvey R.C., Tasian S.K. Clinical diagnostics and treatment strategies for Philadelphia chromosome–like acute lymphoblastic leukemia // Blood Advances 2020; Vol. 4, № 1. P. 218–228.
  188. Moorman A.V., Schwab C., Winterman E., et al. Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL‐class fusion // British Journal of Haematology 2020; Vol. 191, № 5. P. 844–851.
  189. Tasian S.K., Peters C. Targeted therapy or transplantation for paediatric ABL-class Ph-like acute lymphocytic leukaemia? // The Lancet Haematology 2020; Vol. 7, № 12. P. e858–e859.
  190. Childhood ALL Collaborative Group. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukemia: overview of 42 trials involving 12 000 randomised children // Lancet 1996; Vol. 347. P. 1783–1788.
  191. Place A.E., Stevenson K.E., Vrooman L.M., et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial // The Lancet Oncology 2015; Vol. 16, № 16. P. 1677–1690.
  192. Heo Y.A., Syed Y.Y., Keam S.J. Pegaspargase: A Review in Acute Lymphoblastic Leukaemia // Drugs 2019; Vol. 79, № 7. P. 767–777.
  193. Shukla N., Kobos R., Renaud T., et al. Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia // Pediatric Blood & Cancer 2014; Vol. 61, № 3. P. 431–435.
  194. Miano M., Pistorio A., Putti M.C., et al. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients // Leukemia & Lymphoma 2012; Vol. 53, № 9. P. 1693–1698.
  195. Gossai N., Verneris M.R., Karras N.A., et al. A clofarabine-based bridging regimen in patients with relapsed ALL and persistent minimal residual disease (MRD) // Bone Marrow Transplant 2014; Vol. 49, № 3. P. 440–442.
  196. Liu A.P., Lee V., Li C.K., et al. Refractory acute lymphoblastic leukemia in Chinese children: bridging to stem cell transplantation with clofarabine, cyclophosphamide and etoposide // Annals of Hematology 2016; Vol. 95(3). P. 501–507.
  197. Patrick K., Vora A. Update on biology and treatment of T-cell acute lymphoblastic leukaemia // Current Opinion in Pediatrics 2015; Vol. 27, № 1. P. 44–49.
  198. Winter S.S., Dunsmore K.P., Devidas M., et al. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children’s Oncology group Study AALL0434 // Pediatric Blood & Cancer 2015; Vol. 62, № 7. P. 1176–1183.
  199. Hefazi M., Litzow M.R. Recent Advances in the Biology and Treatment of T Cell Acute Lymphoblastic Leukemia // Current Hematologic Malignancy Reports 2018; Vol. 13, № 4. P. 265–274.
  200. Zwaan C.M., Kowalczyk J., Schmitt C., et al. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study // British Journal of Haematology 2017; Vol. 179, № 2. P. 284–293.
  201. Dunsmore K.P., Winter S.S., Devidas M., et al. Children’s Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia // Journal of Clinical Oncology 2020; Vol. 38, № 28. P. 3282–3293.
  202. Shimony S., Liu Y., Valtis Y.K., et al. Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia // Blood Advances 2023; Vol. 7, № 7. P. 1092–1102.
  203. Miller L.H., Maxa K.L., Winter S.S., et al. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities, and future directions // Expert Review of Anticancer Therapy 2023; Vol. 23, № 12. P. 1229–1236.
  204. Patel J., Gao X., Wang H. An Update on Clinical Trials and Potential Therapeutic Strategies in T-Cell Acute Lymphoblastic Leukemia // International Journal of Molecular Sciences 2023; Vol. 24, № 8. P. 7201.
  205. Jeha S., Goto H., Baruchel A., et al. Patient-Level Meta-analysis of Clofarabine in Acute Lymphoblastic Leukemia // Advances in Therapy 2023; Vol. 40, № 12. P. 5447–5463.
  206. Shimony S., DeAngelo D.J., Luskin M.R. Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia // Blood Advances 2024; Vol. 8, № 1. P. 23–36.
  207. Whitlock J.A., Malvar J., Dalla-Pozza L., et al. Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR) // Pediatric Blood & Cancer 2022; Vol. 69, № 11, P. e29901.
  208. Kumamoto T., Goto H., Ogawa C., et al. FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group // International Journal of Hematology 2020; Vol. 112, № 5. P. 720–724.
  209. De Astis E., Clavio M., Raiola A.M., et al. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia // Annals of Hematology 2014; Vol. 93, № 12. P. 2011–2018.
  210. Yılmaz Bengoa Ş., Ataseven E., Kızmazoğlu D., et al. FLAG Regimen with or without Idarubicin in Children with Relapsed/Refractory Acute Leukemia: Experience from a Turkish Pediatric Hematology Center // Turkish Journal of Haematology 2017; Vol. 34, № 1. P. 46–51.
  211. Tavil B., Aytac S., Balci Y.I., et al. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience. Pediatric Hematology and Oncology 2010; Vol. 27, № 7. P. 517–528.
  212. Mustafa O, Abdalla K, AlAzmi AA, et al. FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies // Journal of Oncology Pharmacy Practice 2019; Vol. 25, № 8. P. 1831–1838
  213. Ravichandran N., Uppuluri R., Swaminathan V.V., et al. FLAG With Bortezomib in Childhood Relapsed/Refractory Leukemia: Remission Induction With Limited Toxicity in the Era of Multidrug-resistant Bacteria // Journal of Pediatric Hematology/Oncology 2021; Vol. 43, № 2. P. e212–e214.
  214. Е.В. Семенова, Н.В. Станчева, С.Н. Бондаренко, и др. Лечение рефрактерных форм острого лимфобластного лейкоза у детей и подростков: реиндукция ремиссии с последующей аллогенной трансплантацией гемопоэтических стволовых клеток // Клиническая онкогематология 2013; Том 6, № 1. стр. 54–59.
  215. Дьяконова Ю.Ю., Быданов О.И., Мякова Н.В., и др. Результаты противорецидивной терапии острого лимфобластного лейкоза у детей по пилотному протоколу ALL-REZ-MВ-2014 // Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2017; Том 16, № 3. стр. 7–14.
  216. Дьяконова Ю.Ю., Мякова Н.В., Литвинов Д.В., и др. Первые результаты исследования терапии рецидивов высокой группы риска у детей по пилотному протоколу ALL-REZ-2016 // Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2019; Том 18, № 1. стр. 12–21.
  217. Ribera J.M. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia // Expert Review of Hematology 2017; Vol. 10, № 12. P. 1057–1067.
  218. Algeri M., Del Bufalo F., Galaverna F., et al. Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia // Expert Review of Hematology 2018; Vol. 11, № 12. P. 945–956.
  219. Von Stackelberg A., Locatelli F., Zugmaier G., et al. Phase I/Phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia // Journal of Clinical Oncology 2016; Vol. 34, № 36. P. 4381–4389.
  220. Yu J., Wang W., Huang H. Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin’s lymphoma: a systemic review and meta-analysis // Hematology 2019; Vol. 24, № 1. P. 199–207.
  221. Kantarjian H.M., DeAngelo D.J., Stelljes M., et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia // New England Journal of Medicine 2016; Vol. 375, № 8. P. 740–753.
  222. Rytting M., Triche L., Thomas D., et al. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia // Pediatric Blood & Cancer 2014; Vol. 61, № 2. P. 369–372.
  223. Bhojwani D., Sposto R., Shah N.N., et al. Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia // Leukemia 2019; Vol. 33, № 4. P. 884–892.
  224. Fuster J.L., Molinos-Quintana A., Fuentes C., et al. Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP) // British Journal of Haematology 2020; Vol. 190, № 5. P. 764–771.
  225. Kantarjian H.M., Logan A.C., Zaman F., et al. Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab // Therapeutic Advances in Hematology 2023; Vol. 14.
  226. Xie J., Liu S., Zhou M., et al. Short-course blinatumomab for refractory/relapse precursor B acute lymphoblastic leukemia in children // Frontiers in Pediatrics 2023; Vol. 11.
  227. Chitadze G., Laqua A., Lettau M., et al. Bispecific antibodies in acute lymphoblastic leukemia therapy // Expert Review of Hematology 2020; Vol. 13, № 11. P. 1211–1233.
  228. Contreras C.F., Higham C.S., Behnert A., et al. Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B‐acute lymphoblastic leukemia // Pediatric Blood & Cancer 2021; Vol. 68, № 1. P. e28718.
  229. Pennesi E., Michels N., Brivio E., et al. Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial // Leukemia 2022; Vol. 36, № 6. P. 1516–1524.
  230. Rubinstein J.D., O’Brien M.M. Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations // Frontiers in Immunology 2023; Vol. 14. P. 123773
  231. Kegyes D., Ghiaur G., Bancos A, et al. Immune therapies of B-cell acute lymphoblastic leukaemia in children and adults // Critical Reviews in Oncology/Hematology 2024; Vol. 196. P. 104317.
  232. O’Brien M.M., Ji L., Shah N.N., et al. Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children’s Oncology Group Protocol AALL1621 // Journal of Clinical Oncology 2022; Vol. 40, № 9. P. 956–967.
  233. Gandemer V., Pochon C., Oger E., et al. Clinical value of pre‐transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease‐guided protocol // British Journal of Haematology 2014; Vol. 165, № 3. P. 392–401.
  234. Merli P., Ifversen M., Truong T.H., et al. Minimal Residual Disease Prior to and After Haematopoietic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia: What Level of Negativity Is Relevant? // Frontiers in Pediatrics 2021; Vol. 9. P. 777108
  235. Clements J.D., Zhu M., Kuchimanchi M., et al. Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies // Clinical Pharmacokinetics 2020; Vol. 59, № 4. P. 463–474.
  236. Карачунский А.И., Румянцева Ю.В., Жарикова Л.И., и др. Биспецифическое моноклональное антитело блинатумомаб в первой линии терапии В-линейной острой лимфобластной лейкемии у детей и подростков: промежуточные результаты апробационного протокола Министерства здравоохранения Российской Федерации // Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2024; Том 23, № 1. стр. 14–24.
  237. Попов А.М., Румянцева Ю.В., Михайлова Е.В., et al. Применение блинатумомаба у детей с первичным Ph-негативным В-линейным острым лимфобластным лейкозом и медленным клиренсом минимальной остаточной болезни // Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2024; Том 23, № 1. стр. 63–72.
  238. Hodder A., Mishra A.K., Enshaei A., et al. Blinatumomab for First-Line Treatment of Children and Young Persons With B-ALL // Journal of Clinical Oncology 2024; Vol. 42, № 8. P. 907–914.
  239. Jen E.Y., Xu Q., Schetter A., et al. FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease // Clinical Cancer Research 2019; Vol. 25, № 2. P. 473–477.
  240. Queudeville M., Ebinger M. Blinatumomab in Pediatric Acute Lymphoblastic Leukemia—From Salvage to First Line Therapy (A Systematic Review) // Journal of Clinical Medicine 2021; Vol. 10, № 12. P. 2544.
  241. Gu M., Xia Y., Zhang J., et al. The effectiveness of blinatumomab in clearing measurable residual disease in pediatric B‐cell acute lymphoblastic leukemia patients detected by next‐generation sequencing // Cancer Medicine 2023; Vol. 12, № 24. P. 21978–21984.
  242. Schrappe M., et al. Pediatric Patients with High-Risk B-Cell ALL in First Complete Remission May Benefit from Less Toxic Immunotherapy with Blinatumomab - Results from Randomized Controlled Phase 3 Trial AIEOP-BFM ALL 2017 // Blood 2023; Vol. 142 (Supplement 1). P. 825–825.
  243. Locatelli F., Maschan A., Boissel N., et al. Pediatric patients with acute lymphoblastic leukemia treated with blinatumomab in a real‐world setting: Results from the NEUF study // Pediatric Blood & Cancer 2022; Vol. 69, № 4. P. e29562
  244. Yu C., Jou S.T., Su Y.H., et al. Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia // Cancer 2023; Vol. 129, № 5. P. 790–802.
  245. Arunachalam A.K., Selvarajan S., Mani T., et al. Clinical significance of end of induction measurable residual disease monitoring in B‐cell acute lymphoblastic leukemia: A single center experience // Cytometry Part B-Clinical Cytometry 2023; Vol. 104, № 6. P. 440–452.
  246. Berry D.A., Zhou S., Higley H., et al. Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia // JAMA Oncology 2017; Vol. 3, № 7. P. e170580.
  247. Philipp N., Kazerani M., Nicholls A., et al. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals // Blood 2022; Vol. 140, № 10. P. 1104–1118.
  248. Elitzur S., Arad-Cohen N., Barzilai-Birenboim S., et al. Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B‐cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia // Pediatric Blood & Cancer 2019; Vol. 66, № 10. P. e27898.
  249. Yeoh D.K., Blyth C.C., Kotecha R.S. Blinatumomab as bridging therapy in paediatric B‐cell acute lymphoblastic leukaemia complicated by invasive fungal disease // British Journal of Haematology 2022; Vol. 198, № 5. P. 887–892.
  250. Collignon C., Domenech C., Ducassou S., et al. Temporary contraindication to chemotherapy due to toxicity: blinatumomab’s effectiveness in paediatric patients with B‐acute lymphoblastic leukaemia // British Journal of Haematology 2023; Vol. 201, № 4. P. e42–e45.
  251. Koka A., Saygin C., Uzunaslan D., et al. A 17-year experience with ALL-BFM protocol in acute lymphoblastic leukemia: Prognostic predictors and interruptions during protocol // Leukemia Research 2014; Vol. 38, № 6. P. 699–705.
  252. Suarez A., Piña M., Nichols-Vinueza D.X., et al. A strategy to improve treatment‐related mortality and abandonment of therapy for childhood ALL in a developing country reveals the impact of treatment delays // Pediatric Blood & Cancer 2015; Vol. 62, № 8. P. 1395–1402.
  253. Brown P.A., Ji L., Xu X., et al. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia // JAMA 2021; Vol. 325, № 9. P. 833.
  254. Locatelli F., Zugmaier G., Rizzari C., et al. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia // JAMA 2021; Vol. 325, № 9. P. 843.
  255. Marrapodi M.M., Mascolo A., di Mauro G., et al. The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis // Frontiers in Pediatrics 2022; Vol. 10. P. 929122.
  256. Wadhwa A., Kutny M.A., Xavier A.C. Blinatumomab activity in a patient with Down syndrome B‐precursor acute lymphoblastic leukemia // Pediatric Blood & Cancer 2018; Vol. 65, № 2. P. e26824.
  257. Bailey L.C., Lange B.J., Rheingold S.R., Bunin N.J. Bone marrow relapse in paediatric acute lymphoblastic leukaemia // The Lancet Oncology 2008; Vol. 9, № 9. P. 873–883.
  258. Tallen G., Ratei R., Mann G., et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90 // Journal of Clinical Oncology 2010; Vol. 28, № 14. P. 2339–2347.
  259. Henze G., v Stackelberg A., Eckert C. ALL-REZ BFM – the consecutive trials for children with relapsed acute lymphoblastic leukemia // Klinische Pädiatrie 2013; Vol. 225 (Suppl 1). P. S73–S78.
  260. Hunger S.P., Raetz E.A. How I treat relapsed acute lymphoblastic leukemia in the pediatric population // Blood 2020; Vol. 136, № 16. P. 1803–1812.
  261. Sidhu J., Gogoi M.P., Krishnan S., Saha V. Relapsed Acute Lymphoblastic Leukemia // Indian Journal of Pediatrics 2024; Vol. 91, № 2. P. 158–167.
  262. Eckert C., Parker C., Moorman A.V., et al. Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials // European Journal of Cancer 2021; Vol. 151. P. 175–189.
  263. Nguyen K., Devidas M., Cheng S.C., et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study // Leukemia 2008; Vol. 22, № 12. P. 2142–2150.
  264. Demichelis-Gómez R., Pérez-Sámano D., Bourlon C. Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used // Current Oncology Reports 2019; Vol. 21, № 2. P. 17.
  265. Topp M.S., Stelljes M., Zugmaier G., et al. Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia // Leukemia 2018; Vol. 32, № 2. P. 562–565.
  266. Topp M.S., Gökbuget N., Zugmaier G., et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia // Journal of Clinical Oncology 2014; Vol. 32, № 36. P. 4134–4140.
  267. Locatelli F., Moretta F., Rutella S. Management of relapsed acute lymphoblastic leukemia in childhood with conventional and innovative approaches // Current Opinion in Oncology 2013; Vol. 25, № 6. P. 707–715.
  268. Luskin M.R., Ganetsky A., Landsburg D.J., et al. Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma // British Journal of Haematology 2016; Vol. 174, № 2. P. 332–334.
  269. Cohen M.H., Johnson J.R., Massie T., et al. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma // Clinical Cancer Research 2006; Vol. 12, № 18. P. 5329–5335.
  270. Kathpalia M., Mishra P., Bajpai R., et al. Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis // Annals of Hematology 2022; Vol. 1, № 8. P. 1655–1666.
  271. Дьяконова Ю.Ю., Быданов О.И., Попов А.М.., и др. Роль неларабина в лечении Т-клеточной острой лимфобластной лейкемии: обзор литературы и результаты собственных исследований // Терапевтический архив 2018; Том 90, № 7. стр. 37–50.
  272. Peirs S., Frismantas V., Matthijssens F., et al. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia // Leukemia 2017; Vol. 31, № 10. P. 2037–2047.
  273. Richard-Carpentier G., Jabbour E., Short N.J., et al. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia // Clinical Lymphoma, Myeloma and Leukemia 2020; Vol. 20, № 4. P. 212–218.
  274. Farhadfar N., Li Y., May W.S., Adams C.B. Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: A case report and review of literature // Hematology/Oncology and Stem Cell Therapy 2021; Vol. 14, № 3. P. 246–251.
  275. La Starza R., Cambò B., Pierini A., et al. Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia // JCO Precision Oncology 2019; Vol. 3.
  276. Zhu Y., Dai Y., Tang X. Venetoclax combined with decitabine and HAAG regimen: a novel salvage strategy for relapsed/refractory T-cell acute lymphoblastic leukaemia // Annals of Hematology 2022; Vol. 101, № 11. P. 2525–2528.
  277. Arora S., Vachhani P., Bachiashvili K., Jamy O. Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia // Leukemia & Lymphoma 2021; Vol. 62, № 9. P. 2292–2294.
  278. Gibson A., Trabal A., McCall D., et al. Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma // Cancers (Basel) 2021; Vol. 14, № 1. P. 150.
  279. Pullarkat V.A., Lacayo N.J., Jabbour E., et al. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma // Cancer Discovery 2021; Vol. 11, № 6. P. 1440–1453.
  280. Leśniak M., Lipniarska J., Majka P., et al. Recent Updates in Venetoclax Combination Therapies in Pediatric Hematological Malignancies. International Journal of Molecular Sciences 2023; Vol. 24, № 23. P.16708.
  281. Zhou H., Zheng C., Zhu X., et al. Decitabine prior to salvaged unrelated cord blood transplantation for refractory or relapsed childhood acute leukemia // Pediatric Transplantation 2016; Vol. 20, № 8. P. 1117–1124
  282. Li T., Cui Q., Liu S., et al. Decitabine consolidation after CD19/CD22 CAR-T therapy as a novel maintenance treatment significantly improves survival outcomes in relapsed/refractory B-ALL patients // Leukemia Research 2024; Vol. 145. P. 107569
  283. Румянцев А.Г., Масчан А.А., Биккулова Д.Ш. Федеральные клинические рекомендации по организации оптимального венозного доступа у детей с гематологическими, онкологическими и иммунологическими заболеваниями. Официальное издание. НОДГО. Москва, 2015, 20 с.
  284. Сацук А.В., Солопова Г.Г., Щукин В.В., и др. Венозный катетер. Использование, уход, контроль, осложнения: учебное пособие. М. АО «Информатика», 2023, 152 с.
  285. Coiffier B., Altman A., Pui C.H., et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review // Journal of Clinical Oncology 200;. Vol. 26, № 16. P. 2767–2778.
  286. Cairo M.S., Coiffier B., Reiter A., et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: An expert TLS panel consensus // British Journal of Haematology 2010; Vol. 149, № 4. P. 578–586.
  287. Jones G.L., Will A., Jackson G.H., et al. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology // British Journal of Haematology 2015; Vol. 169, № 5. P. 661–671.
  288. Perissinotti A.J., Bishop M.R., Bubalo J., et al. Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: Results of a modified Delphi panel // Cancer Treatment Reviews 2023; Vol. 120. P. 102603.
  289. Cheung W.L., Hon K.L., Fung C.M., Leung A.K. Tumor lysis syndrome in childhood malignancies // Drugs in Context 2020; Vol. 9.
  290. Agrawal A.K., Chang P.P., Feusner J. Twice weekly pneumocystis jiroveci pneumonia prophylaxis with trimethoprim-sulfamethoxazole in pediatric patients with acute lymphoblastic leukemia // Journal of Pediatric Hematology/Oncology 2011; Vol. 33, № 1. P. e1–e4.
  291. Schrøder H., Agger K.E., Rosthøj S., et al. Antibacterial prophylaxis with trimethoprim-sulfamethoxazole during induction treatment for acute lymphoblastic leukemia // Danish medical bulletin 2001; Vol. 48, № 4. P. 275–277.
  292. Taplitz R.A., Kennedy E.B., Bow E.J., et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update // Journal of Clinical Oncology 2018; Vol. 36, № 14. P. 1443–1453.
  293. Hakim H., Flynn P.M., Knapp K.M., et al. Etiology and clinical course of febrile neutropenia in children with cancer // Journal of Pediatric Hematology/Oncology 2009; Vol. 31, № 9. P. 623–629.
  294. Tam C.S., O'Reilly M., Andresen D., et al. Use of empiric antimicrobial therapy in neutropenic fever. Australian Consensus Guidelines 2011 Steering Committee // Internal Medicine Journal 2011; Vol. 41, № 1b. P. 90–101.
  295. Li Y., Gong Y.H., Zhao M.F., et al. Ileus induced by the combination of vinca alkaloids and posaconazole in a patient with acute lymphoblastic leukemia: a case report and literature review // Journal of International Medical Research 2023; Vol. 51, № 8.
  296. Moriyama B., Henning S.A., Leung J., et al. Adverse interactions between antifungal azoles and vincristine: review and analysis of cases // Mycoses 2012; Vol. 55, № 4. P. 290–297.
  297. Castells G., Rodríguez-Reyes M., Chaguaceda C., et al. Paralytic Ileus and Syndrome of Inappropriate Antidiuretic Hormone Secretion Potentially due to an Interaction Between Vincristine and Voriconazole/Posaconazole // American Journal of Therapeutics 2019; Vol. 26, № 6. P. e722–e723.
  298. Pekpak E., İleri T., İnce E., et al. Toxicity of Vincristine Combined With Posaconazole in Children With Acute Lymphoblastic Leukemia // Journal of Pediatric Hematology/Oncology 2018; Vol. 40, № 5. P. e309–e310.
  299. Yang L., Yu L., Chen X., et al. Clinical Analysis of Adverse Drug Reactions between Vincristine and Triazoles in Children with Acute Lymphoblastic Leukemia // Medical Science Monitor 2015; Vol. 21: 1656-61.
  300. Monagle P., Cuello C.A., Augustine C., et al. American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism // Blood Advances 2018; Vol. 2, № 22. P. 3292–3316.
  301. Monagle P., Chan A.K.C., Goldenberg N.A., et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines // Chest 2012; Vol. 141 (2 Suppl). P. e737S–e801S.
  302. Свирин П.В., Ларина Л.Е., Жарков П.А., и др. Педиатрические тромбозы: применение далтепарина натрия для лечения и профилактики // Российский журнал детской гематологии и онкологии (РЖДГиО) 2015; Том 2, № 1. стр. 61–65.
  303. Жарков П.А., Ершов Н.М., Пшонкин А.В. Эффективность и безопасность применения низкомолекулярных гепаринов у детей с тромбозами правого предсердия // Тромбоз, гемостаз и реология 2018; Том 73, № 1. стр. 61–65.
  304. Жарков П.А., Шифрин Ю.А., Новичкова Г.А. Эффективность антитромботической терапии тромбозов глубоких вен у детей с заболеваниями крови // Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2019; Том 18, № 1. стр. 34–42.
  305. Морозова Д.С., Евстратов Д.А., Жарков П.А. Рецидивирующее течение тромбозов глубоких вен у детей со злокачественными заболеваниями крови: обзор литературы // Онкогематология 2019; Том 14, № 2. стр. 24–28.
  306. Brandão L.R., Tartakovsky I., Albisetti M., et al. Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia // Blood Advances 2022; Vol. 26, № 22. P. 5908–5923.
  307. Connor P., Sánchez van Kammen M., Lensing A.W.A., et al. Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT) // Blood Advances 2020; Vol. 4, № 24. P. 6250–6258.
  308. Thom K., Lensing A.W.A., Nurmeev I., et al. Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE) // Blood Advances 2020; Vol. 4, № 19. P. 4632–4639.
  309. Palumbo J.S., Lensing A.W.A., Brandão L.R., et al. Anticoagulation in pediatric cancer-associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr // Blood Advances 2022; Vol. 6, № 22. P. 5821–5828.
  310. Жарикова Л.И., Румянцева Ю.В., Карачунский А.И. Тромбозы у детей с острым лимфобластным лейкозом // Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2015; Том 14, № 3. стр. 39–47.
  311. van Ommen C.H., van den Dool E.J., Peters M. Nadroparin therapy in pediatric patients with venous thromboembolic diseas // Journal of Pediatric Hematology/Oncology 2008; Vol. 30, № 3. P. 230–234
  312. Shen X., Wile R., Young G. FondaKIDS III: A long-term retrospective cohort study of fondaparinux for treatment of venous thromboembolism in children. Pediatric Blood & Cancer 2020; Vol. 67, № 8. P. e28295.
  313. Федорова Д.В., Жарков П.А., Пшонкин А.В., и др. Эффективность и безопасность off-label применения эптакога альфа у педиатрических пациентов гематологического и онкологического профиля // Тромбоз, гемостаз и реология 2018; Том 76, №4. стр. 44–53.
  314. Ueda M., Berger M., Gale R.P., Lazarus H.M. Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation // Blood Reviews 2018; Vol. 32, № 2. P. 106–115.
  315. Essa M.F., Abdellatif R., Elimam N., et al. Outcomes of blinatumomab based therapy in children with relapsed, persistent, or refractory acute lymphoblastic leukemia: a multicenter study focusing on predictors of response and post-treatment immunoglobulin production // Pediatric Hematology and Oncology 2022; Vol. 39, № 7. P. 613–628.
  316. Абузарова Г.Р., Невзорова Д.В., Кумирова Э.В. и др. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России., 2016, 94 с.
  317. Lim Y.J., Park E.K., Koh H.C., Lee Y.H. Syndrome of inappropriate secretion of antidiuretic hormone as a leading cause of hyponatremia in children who underwent chemotherapy or stem cell transplantation // Pediatric Blood & Cancer 2010; Vol. 54, № 5. P. 734–737.
  318. Yasir M., Mechanic O.J. Syndrome of Inappropriate Antidiuretic Hormone Secretion. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024
  319. Дзагахова А.В., Катамадзе Н.Н., Пигарова Е.А. Синдром неадекватной секреции антидиуретического гормона в практике эндокринолога // Эндокринная хирургия 2020; Том 14, № 3. стр. 4–12.
  320. Patel P., Robinson P.D., Wahib N., et al. Interventions for the prevention of acute phase chemotherapy-induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis // Supportive Care in Cancer 2022; Vol. 30, № 11. P. 8855–8869.
  321. Васильева Е.С., Вашура А.Ю., Литвинов Д.В. Нутритивный статус детей с онкологическими и гематологическими заболеваниями, находящихся на лечении в ФГБУ «ФНКЦ ДГОИ им. Дмитрия Рогачева» (результаты скринингового исследования) // Современная онкология 2016; Том 18, № 4. стр. 48–52.
  322. Muscaritoli M., Arends J. Bachmann P., et al. ESPEN practical guideline: Clinical Nutrition in cancer // Clinical Nutrition 2021; Vol. 40, № 5. P. 2898–2913.
  323. Joosten K., Embleton N., Yan W., et al. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Energy // Clinical Nutrition 2018; Vol. 37, № 6 (Pt B). P. 2309–2314.
  324. Gaudichon J., Jakobczyk H., Debaize L., et al. Mechanisms of extramedullary relapse in acute lymphoblastic leukemia: Reconciling biological concepts and clinical issues // Blood Reviews 2019; Vol. 36. P. 40–56.
  325. Carolan A., Batie S., Rakheja D., et al. Testicular relapse of acute lymphoblastic leukemia // Urology Case Reports 2023; Vol. 50. P. 102449.
  326. Hill F.G.H., Richards S., Gibson B., et al. Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: Results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172) // British Journal of Haematology 2004; Vol. 124, № 1. P. 33–46.
  327. Kelly M.J., Trikalinos T.A. Dahabreh I.J., et al. Cranial radiation for pediatric T-lineage acute lymphoblastic leukemia: A systematic review and meta-analysis // American Journal of Hematology 2014; Vol. 89, № 10. P. 992–997.
  328. Vora A., Andreano A., Pui C.H., et al. Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy // Journal of Clinical Oncology 2016; Vol. 34, № 9. P. 919–926.
  329. McNeer J.L., Schmiegelow K. Management of CNS Disease in Pediatric Acute Lymphoblastic Leukemia // Current Hematologic Malignancy Reports 2022; Vol. 17, № 1. P. 1–14.
  330. Wu S.Y., Short N.J., Nasr L., et al. Central Nervous System Prophylaxis and Treatment in Acute Leukemias // Current Treatment Options in Oncology 2022; Vol. 23, № 12. P. 1829–1844.
  331. Нечеснюк А.В., Виллих Н.А. Стандартизация в современной лучевой терапии пациентов детского возраста // Российский журнал детской гематологии и онкологии (РЖДГиО) 2016; Том 3, № 2. стр. 46–49.
  332. Dave D.S., Leppert J.T., Rajfer J. Is the testis a chemo-privileged site? Is there a blood-testis barrier? // Reviews in urology 2007; Vol. 9, № 1. P. 28–32.
  333. Peters C., Dalle J.H., Locatelli F., et al. Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study // Journal of Clinical Oncology 2021; Vol. 39, № 4. P. 295–307.
  334. Hoeben B.A.W., Pazos M., Seravalli E., et al. ESTRO ACROP and SIOPE recommendations for myeloablative Total Body Irradiation in children // Radiotherapy and Oncology 2022; Vol. 173. P. 119–133.
  335. Rehman M.E.U., Chattaraj A., Mahboob A., et al. Total Body Irradiation Versus Chemotherapy Conditioning in Pediatric Acute Lymphoblastic Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant: A Systematic Review and Meta-Analysis // Clinical Lymphoma, Myeloma and Leukemia 2023; Vol. 23; № 4. P. 249–258.
  336. Khimani F., Dutta M., Faramand R., et al. Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis // Transplantation and Cellular Therapy 2021; Vol. 27, № 7. P. 620.e1–620.e9.
  337. Dholaria B., Labopin M., Angelucci E., et al. Improved Outcomes of Haploidentical Hematopoietic Cell Transplantation with Total Body Irradiation-Based Myeloablative Conditioning in Acute Lymphoblastic Leukemia // Transplantation and Cellular Therapy 2021; Vol. 27, № 2. P. 171.e1–171.e8.
  338. Aamir S., Anwar M.Y., Khalid F., et al. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes // Clinical Lymphoma, Myeloma and Leukemia 2021; Vol. 21, № 4. P. e334–e347.
  339. Sheykhhasan M., Manoochehri H., Dama P. Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study // Cancer Gene Therapy 2022; Vol. 29, № 8-9. P. 1080–1096.
  340. Knight E.T., Oluwole O., Kitko C. The Implementation of Chimeric Antigen Receptor (CAR) T-cell Therapy in Pediatric Patients: Where Did We Come From, Where Are We Now, and Where are We Going? // Clinical Hematology International 2024; Vol. 6, № 1. P. 96–115.
  341. Lato M.W., Przysucha A., Grosman S., et al. The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia // International Journal of Molecular Sciences 2021; Vol. 22, № 9. P. 4502.
  342. Pehlivan K.C., Duncan B.B., Lee D.W. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease // Current Hematologic Malignancy Reports 2018; Vol. 13, № 5. P. 396–406.
  343. Zhai Y., Hong J., Wang J., et al. Comparison of blinatumomab and CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia: a systematic review and meta-analysis // Expert Review of Hematology 2024; Vol. 17, № 1-3. P. 67–76.
  344. Cao X.Y., Li J.J., Lu P.H., Liu K.Y. Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation // International Journal of Hematology 2022; Vol. 116, № 3. P. 315–329.
  345. Rogosic S., Ghorashian S. CAR-T cell therapy in paediatric acute lymphoblastic leukaemia - past, present and future // British Journal of Haematology 2020; Vol. 191, № 4. P. 617–626.
  346. Qayed M., Bleakley M., Shah N.N. Role of chimeric antigen receptor T-cell therapy: bridge to transplantation or stand-alone therapy in pediatric acute lymphoblastic leukemia // Current Opinion in Hematology 2021; Vol. 28, № 6. P. 373–379.
  347. Tian J., Wei A., Wang B., et al. Allogeneic hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia // Annals of Hematology 2024; Vol. 103, № 1. P. 297–305.
  348. Khazal S., Kebriaei P. Hematopoietic cell transplantation for acute lymphoblastic leukemia: review of current indications and outcomes // Leukemia & Lymphoma 2021; Vol. 62, № 12. P. 2831–2844.
  349. Algeri M., Merli P., Locatelli F., Pagliara D. The Role of Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Leukemia // Journal of Clinical Medicine 2021; Vol. 10, № 17. P. 3790.
  350. Peters C., Locatelli F., Bader P. Acute Lymphoblastic Leukemia in Children and Adolescents // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 539–547.
  351. Dworzak M.N., Fröschl G., Printz D., et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia // Blood 2002; Vol. 99, № 6. P. 1952–1958.
  352. Abou Dalle I., Jabbour E., Short N.J. Evaluation and management of measurable residual disease in acute lymphoblastic leukemia // Therapeutic Advances in Hematology 2020; Vol. 11.
  353. Eckert C., Hagedorn N., Sramkova L., et al. Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment // Leukemia 2015; Vol. 29, № 8. P. 1648–1655.
  354. Масчан М.А. Деплеция альфа/бета-Т-лимфоцитов – надежная платформа для развития трансплантации гемопоэтических стволовых клеток от гаплоидентичных доноров // Российский журнал детской гематологии и онкологии (РЖДГиО) 2015; Том 2, № 3. стр. 34–38.
  355. Aversa F., Terenzi A., Tabilio A., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse // Journal of Clinical Oncology 2005; Vol. 23, № 15. P. 3447–3454.
  356. August K.J., Narendran A., Neville K.A. Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions // Drugs 2013; Vol. 73, № 5. P. 439–461.
  357. Eckert C., Henze G., Seeger K., et al. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group // Journal of Clinical Oncology 2013; Vol. 31, № 21. P. 2736–2742.
  358. Sharma A., Rastogi N., Chatterjee G., et al. Haploidentical Stem Cell Transplantation With Post-transplant Cyclophosphamide for Pediatric Acute Leukemia is Safe and Effective // Journal of Pediatric Hematology/Oncology 2021; Vol. 43, № 7. P. e1033–e1036.
  359. Zhou B., Xu M., Lu S., et al. Clinical Outcomes of B Cell Acute Lymphoblastic Leukemia Patients Treated with Haploidentical Stem Cells Combined with Umbilical Cord Blood Transplantation // Transplantation and Cellular Therapy 2022; Vol. 28, № 3. P. 173.e1–173.e6.
  360. Owattanapanich W., Leelakanok N., Sanpakit K., Buaboonnam J. A Comparison of the Clinical Outcomes of Haploidentical Transplantation and Other Graft Sources in Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis // Clinical Lymphoma, Myeloma and Leukemia 2022; Vol. 22, № 3. P. 174–191.
  361. Moreno C., Ramos-Elbal E., Velasco P., et al. Haploidentical vs. HLA-matched donor hematopoietic stem-cell transplantation for pediatric patients with acute lymphoblastic leukemia in second remission: A collaborative retrospective study of the Spanish Group for Bone Marrow Transplantation in Children (GETMON/GETH) and the Spanish Childhood Relapsed ALL Board (ReALLNet) // Frontiers in Pediatrics 2023; Vol. 11. P. 1140637.
  362. Wieduwilt M.J., Metheny L., Zhang M.J., et al. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia // Blood Advances 2022; Vol. 6, № 1. P. 339–357.
  363. L’Hotta A.J., Randolph S.B., Reader B., et al. Clinical practice guideline and expert consensus recommendations for rehabilitation among children with cancer: A systematic review // CA: A Cancer Journal for Clinicians 2023; Vol. 73, № 5. P. 524–545.
  364. Ospina P.A., Wiart L., Eisenstat D.D., McNeely M.L. Physical Rehabilitation Practices for Children and Adolescents with Cancer in Canada // Physiotherapy Canada 2020; Vol.. 72, № 2. P. 207–216.
  365. Fischmeister G., Riedl D., Sanio G., et al. Rehabilitation for children and adolescents after cancer: importance and implementation in Austria // Memo 2021; Vol. 14. P. 278–283.
  366. Баринкова ЕА., и др. Диспансерное наблюдение детей с гематологическими заболеваниями в детской поликлинике. Методические рекомендации. Под ред. Румянцева А.Г., Финогеновой Н.А. ГОУ ВПО РГМУ им. Н.И.Пирогова, 2008.
  367. Шарапова Г.Р., Румянцева Ю.В., Бойченко Э.Г., и др. Терапия Т-клеточного острого лимфобластного лейкоза у детей: опыт Российско-Белорусской кооперированной группы // Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2015; Том 14, № 1. стр. 26–37
  368. Пшонкин А.В., Румянцева Ю.В., Литвинов Д.В., и др. Лечение острого лимфобластного лейкоза у подростков и молодых взрослых: опыт Москва–Берлин // Российский журнал детской гематологии и онкологии (РЖДГиО) 2016; Том 3, № 1. стр. 35–43
  369. Popov A., Henze G., Roumiantseva J., et al. A Single Dose of PEG-Asparaginase at the Beginning of Induction Not Only Accelerates MRD Clearance but Also Improves Long-Term Outcome in Children with B-Lineage ALL // Cancers (Basel) 2023; Vol. 15, № 23. P. 5547
  370. Biondi A., Schrappe M., De Lorenzo P., et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study // The Lancet Oncology 2012; Vol. 13, № 9. P. 936–945
  371. Lynggaard L.S., Rank C.U., Als-Nielsen B., et al. PEG-asparaginase treatment regimens for acute lymphoblastic leukaemia in children: a network meta-analysis // Cochrane Database of Systematic Reviews 2023; Vol. 5, № 5. CD014570
  372. Mesegué M., Alonso-Saladrigues A., Pérez-Jaume S., et al. Lower incidence of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia // Hematological Oncology 2021; Vol. 39, № 5. P. 687–696
  373. Sidhu J., Masurekar A.N., Gogoi M.P., et al. Activity and toxicity of intramuscular 1000 iu/m2 polyethylene glycol-E. coli L-asparaginase in the UKALL 2003 and UKALL 2011 clinical trials // British Journal of Haematology 2022; Vol. 198, № 1. P. 142–150
  374. Derman B.A., Streck M., Wynne J., et al. Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia // Leukemia & Lymphoma 2020; Vol. 61, № 3. P. 614–622.
  375. Kloos R.Q.H., Pieters R., Jumelet F.M.V., et al. Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia // Journal of Clinical Oncology 2020; Vol. 38, № 7. P. 715–724.
  376. Teachey D.T., Devidas M., Wood B.L., et al. Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma // Journal of Clinical Oncology 2022; Vol. 40, № 19. P. 2106–2118
  377. Miyagawa N., Goto H., Ogawa A., et al. Phase 2 study of combination chemotherapy with bortezomib in children with relapsed and refractory acute lymphoblastic leukemia // International Journal of Hematology 2023; Vol. 118, № 2. P. 267–276
  378. Iguchi A., Cho Y., Sugiyama M., et al. Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia // International Journal of Hematology 2017; Vol. 106, № 2. P. 291–298
  379. Bertaina A., Vinti L., Strocchio L., et al. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood // British Journal of Haematology 2017; Vol. 176, № 4. P. 629–636
  380. Валиев Т.Т., Шервашидзе М.А., Осипова И.В., и др. Протокол ALL-IC BFM 2002: результаты лечения острого лимфобластного лейкоза у детей в рамках многоцентрового клинического исследования // Клиническая онкогематология 2022; Том 15, № 2. стр. 119–29.
  381. Литвинов Д.В., Мякова Н.В., Алейникова О.В., и др. Острый лимфобластный лейкоз высокого риска в исследовании ALL-MB 2002 // Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2022; Том 21, № 3. стр. 28–41
  382. Chen A.R., Wang Y.M., Lin M., Kuo D.J. High-Dose Methotrexate in Pediatric Acute Lymphoblastic Leukemia: Predictors of Delayed Clearance and the Effect of Increased Hydration Rate on Methotrexate Clearance // The Cureus Journal of Medical Science 2020; Vol. 12, № 6. P. e8674.
  383. Sajith M., Pawar A., Bafna V., et al. Serum Methotrexate Level and Side Effects of High Dose Methotrexate Infusion in Pediatric Patients with Acute Lymphoblastic Leukaemia (ALL) // Indian Journal of Hematology and Blood Transfusion 2020; Vol. 36, № 1. P. 51–58
  384. Parker C., Waters R., Leighton C., et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial // The Lancet 2010; Vol. 376, № 9757. P.2009–2017
  385. Higashigawa M., Hori H., Hirayama M., et al. Salvage therapy for relapsed or refractory childhood acute lymphocytic leukemia by alternative administration a lymphoid- and myeloid-directed chemotherapeutic regimen consisting of dual modulation of ara-C, hydroxyurea, and etoposide // Leukemia Research 1997; Vol. 21, № 9. P. 811–815
  386. Kern W., Schleyer E., Braess J., et al. Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias // Annals of Hematology 2001; Vol. 80, № 6. P. 334–339
  387. Hayashi R.J., Winter S.S., Dunsmore K.P., et al. Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434 // Journal of Clinical Oncology 2020; Vol. 38, № 26. P. 3062–3070
  388. Von Stackelberg A., Harms D., Klingebiel T., et al. Improved outcome after relapse of childhood ALL: Results of trial ALL-REZ BFM 95/96 // Medical and Pediatric Oncology 2002; Vol. 39. P. 236.
  389. Herold R., von Stackelberg A., Hartmann R., et al. Acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group (ALL-REZ BFM) experience: early treatment intensity makes the difference // Journal of Clinical Oncology 2004; Vol. 22, № 3. P. 569–570.
  390. Eckert C., von Stackelberg A., Seeger K., et al. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia – long-term results of trial ALL-REZ BFM P95/96 // European Journal of Cancer 2013; Vol. 49, № 6. P. 1346–1355.
  391. Ayuk F., Balduzzi A. Donor Selection for Adults and Pediatrics // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies / ed. Carreras E. et al. Springer, 2019. P. 87–99.
  392. Gibson B.E.S., Sauer M.G., Amrolia P. Acute Myeloid Leukemia in Children // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 523–531.
  393. Carreras E., Rambaldi A. Evaluation and Counseling of Candidates // EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 77–87.
  394. Confer D.L., Miller J.P., Chell J.W. Bone Marrow and Peripheral Blood Cell Donors and Donor Registries // Thomas’ Hematopoietic Cell Transplantation 2016; Vol. 1–2. P. 423–432.
  395. Witt V., Peters C. Collection of HSC in Children // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 123–127.
  396. Witt V., Pichler H. Mobilization and Collection of HSCs in Children // The EBMT Handbook Hematopoietic Cell Transplantation and Cellular Therapies. ed. Anna Sureda et al. Springer, 2024 P. 159–116.
  397. Gorin N.C. Bone Marrow Harvesting for HSCT // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 109–117.
  398. Hübel K. Mobilization and Collection of HSC // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 117–123.
  399. Kurnikova E., Trakhtman P., Balashov D., et al. Efficacy and safety of a reduced dose of plerixafor in combination with granulocyte colony-stimulating factor in healthy haploidentical stem cell donors // Vox Sanguinis 2022; Vol. 117, № 6. P.853–861.
  400. Балашов Д.Н., Курникова Е.Е., Масчан М.А., и др. Применение плериксафора для мобилизации гемопоэтических стволовых клеток у доноров аллогенного трансплантата // Онкогематология 2014; Том 9, № 4. стр. 24–27.
  401. Querol S., Rocha V. Procurement and Management of Cord Blood // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 131–137.
  402. Wuchter P. Processing, Cryopreserving and Controlling the Quality of HSCs // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 127–131.
  403. Schumm M., Lang P., Handgretinger R. Graft Manipulation // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 137–143.
  404. Nagler A., Shimoni A. Conditioning // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 99–109.
  405. Peters C., Dalle J.H., Locatelli F., et al. Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study // Journal of Clinical Oncology 2021; Vol. 39, № 4. P. 295–307.
  406. Ansari F., Behfar M., Jafari L., et al A comprehensive comparison between TBI vs non-TBI-based conditioning regimen in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis // Leukemia Research 2023; Vol. 135. P. 107416.
  407. Bader P., et al. Monitoring Measurable Residual Disease in ALL and AML// The EBMT Handbook Hematopoietic Cell Transplantation and Cellular Therapies. ed. Anna Sureda et al. Springer, 2024. P. 513-523
  408. Penack O., Marchetti M., Ruutu T., et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation // The Lancet Haematology 2020; Vol. 7, № 2. P. e157–e167.
  409. Michonneau D., Socié G. GVHD Prophylaxis (Immunosuppression) // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 177–183.
  410. Watanabe N. et al. Relationship between tacrolimus blood concentrations and clinical outcome during the first 4 weeks after SCT in children // Bone Marrow Transplantation 2010; Vol. 45, № 7. P. 1161–1166.
  411. Sandmaier B.M., Maloney D.G., Storer B.E., et al. Sirolimus Combined with Mycophenolate Mofetil (MMF) and Cyclosporine (CSP) Significantly Improves Prevention of Acute Graft-Versus-Host-Disease (GVHD) after Unrelated Hematopoietic Cell Transplantation (HCT): Results from a Phase III Randomized Multi-Center Trial. Blood 2016; Vol. 128, № 22. P. 506
  412. Boelens J.J., et al. GVHD Prophylaxis // The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies. ed. Anna Sureda et al. Springer, 2024; Chapter 26.
  413. Jacoby E., Chen A., Loeb D.M., et al. Single agent post-transplantation cyclophosphamide as GVHD prophylaxis after HLA-matched related BMT for pediatric and young adult patients with hematologic malignancies // Biology of Blood and Marrow Transplantation 2016; Vol. 22, № 1. P. 112.
  414. Baron F., Mohty M., Blaise D., et al. Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation // Haematologica 2017; Vol. 102, № 2. P. 224–234.
  415. Koreth J., Kim H.T., Lange P.B., et al. Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results // Haematologica 2018; Vol. 103, № 3. P. 522–530.
  416. Wertheimer T., Dohse M., Afram G., et al. Abatacept as salvage therapy in chronic graft-versus-host disease—a retrospective analysis // Annals of Hematology 2021; Vol. 100, № 3. P. 779–787.
  417. Drobyski W.R., Pasquini M., Kovatovic K., et al. Tocilizumab for the Treatment of Steroid Refractory Graft-versus-Host Disease // Biology of Blood and Marrow Transplantation 2011; Vol. 17, № 12. P. 1862–1868.
  418. Dunaikina M., Zhekhovtsova Z., Shelikhova L., et al. Safety and efficacy of the low-dose memory (CD45RA-depleted) donor lymphocyte infusion in recipients of αβ T cell-depleted haploidentical grafts: results of a prospective randomized trial in high-risk childhood leukemia // Bone Marrow Transplantation 2021; Vol. 56, № 7. P. 1614–1624.
  419. Abouelnasr A., Roy J., Cohen S., et al. Defining the Role of Sirolimus in the Management of Graft-versus-Host Disease: From Prophylaxis to Treatment // Biology of Blood and Marrow Transplantation 2013; Vol. 19. P. 12–21.
  420. Schäfer H., Blümel-Lehmann J., Ihorst G., et al. A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT // Annals of Hematology 2021; Vol. 100, № 8. P. 2095–2103.
  421. Chao Y.H., Chang Y.C., Wu H.P., et al. Everolimus for pediatric patients with acute graft-versus-host disease after hematopoietic stem cell transplantation: A pilot study // Medicine (Baltimore) 2017; Vol. 96, № 44. P. e8464.
  422. Malard F., Labopin M., Yakoub-Agha I., et al. Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study // Blood 2017; Vol. 130, № 20. P. 2186–2195.
  423. Shelikhova L., Glushkova S., Nikolaev R., et al. Serotherapy-Free Regimen Improves Non-Relapse Mortality and Immune Recovery Among the Recipients of αβ TCell-Depleted Haploidentical Grafts: Retrospective Study in Childhood Leukemia // Transplantation and Cellular Therapy 2021; Vol. 27, № 4. P. 330.e1–330.e9.
  424. Wolff D., Lawitschka A. Chronic Graft-Versus-Host Disease // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 331–347.
  425. Chen Y.B., Mohty M., Zeiser R., et al. Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial // Nature Medicine 2024; Vol. 30, № 8. P. 2277–2287
  426. Fukuta T., Muramatsu H., Yamashita D., et al. Vedolizumab for children with intestinal graft-versus-host disease: a case report and literature review // International Journal of Hematology 2023; Vol. 118, № 3. P. 411–417
  427. Atia O., Shavit-Brunschwig Z., Mould D.R., et al. Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study. The Lancet Gastroenterology & Hepatology 2023; Vol. 8, № 1. P. 31–42
  428. Locatelli F., Antmen B., Kang H.J., et al. Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study // The Lancet Haematology 2024; Vol. 11, № 8. P. e580–e592
  429. Cutler C., Antin J.H. Manifestations and Treatment of Acute Graft-versus-Host Disease // Thomas’ Hematopoietic Cell Transplantation 2016; Vol. 2–2. P. 1012–1025.
  430. Toubai T., Magenau J. Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease // Blood 2020; Vol. 136, № 4. P. 429–440.
  431. Martin P.J. How I treat steroid-refractory acute graft-versus-host disease // Blood 2020; Vol. 135, № 19. P. 1630–1638.
  432. Bacigalupo A., Milone G., Cupri A., et al. Steroid treatment of acute graft-versus-host disease grade I: a randomized trial // Haematologica 2017; Vol. 102, № 12. P. 2125–2133.
  433. Nassar A., Elgohary G., Elhassan T., et al. Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation // Journal of Transplantation 2014; Vol. 2014. P. 1–10.
  434. Kawashima N., Iida M., Suzuki R., et al. Prophylaxis and treatment with mycophenolate mofetil in children with graft-versus-host disease undergoing allogeneic hematopoietic stem cell transplantation: a nationwide survey in Japan // International Journal of Hematology 2019; Vol. 109, № 4. P. 491–498.
  435. Khandelwal P., Lawrence J., Filipovich A.H., et al. The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients // Pediatric Transplantation 2014; Vol. 18, № 1. P. 94–102.
  436. González Vicent M., Molina B., González de Pablo J., et al. Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results // American Journal of Hematology 2019; Vol. 94, № 3. P. 319–326.
  437. Faraci M., Calevo M.G., Giardino S., et al. Etanercept as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients // Biology of Blood and Marrow Transplantation 2019; Vol. 25, № 4. P. 743–748.
  438. Agarwal N., Rotz S., Hanna R. Medical emergencies in pediatric blood & marrow transplant and cellular therapies // Frontiers in Pediatrics 2023; Vol. 11. P. 1075644.
  439. Sleight B.S., Chan K.W., Braun T.M., et al. Infliximab for GVHD therapy in children // Bone Marrow Transplantation 2007; Vol. 40, № 5. P. 473–480.
  440. Albert M.H., Becker B., Schuster F.R., et al. Oral graft vs. host disease in children - Treatment with topical tacrolimus ointment // Pediatric Transplantation 2007; Vol. 11, № 3. P. 306–309.
  441. Zangrilli A., Campione E., Diluvio L., et al. Treatment of disfiguring chronic graft versus host disease in a child with topical pimecrolimus // Pediatrics International 2010; Vol. 52, № 3. P. e161–e163.
  442. Baird K., Comis L.E., Joe G.O., et al. Imatinib Mesylate for the Treatment of Steroid-Refractory Sclerotic-Type Cutaneous Chronic Graft-versus-Host Disease // Biology of Blood and Marrow Transplantation 2015; Vol. 21, № 6. P. 1083–1090.
  443. Filipovich A.H., et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report // Biology of Blood and Marrow Transplantation 2005; Vol. 11, № 12. P. 945–956.
  444. Jagasia M.H., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report // Biology of Blood and Marrow Transplantation 2015; Vol. 21, № 3. P. 389-401
  445. Carpenter P.A., Kitko C.L., Elad S., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report // Biology of Blood and Marrow Transplantation 2015; Vol. 21, № 7. P. 1167–1187.
  446. Martin P.J., Inamoto Y., Carpenter P.A., et al. Treatment of chronic graft-versus-host disease: Past, present and future // The Korean Journal of Hematology 2011; Vol. 46, № 3. P. 153–163.
  447. Flowers M.E., Martin P.J. How we treat chronic graft-versus-host disease // Blood 2015; Vol. 125, № 4. P. 606–615.
  448. Inamoto Y., Flowers M.E., Sandmaier B.M., et al. Failure-free survival after initial systemic treatment of chronic graft-versus-host disease // Blood 2014; Vol. 124, № 8. P. 1363–1371.
  449. Penack O., Marchetti M., Ruutu T., et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantion // The Lancet Haematology 2020; Vol. 7, № 2. P. e157–e167
  450. Zeiser R., Fatoum H., Hashmi S.K. A personalized, organ-based approach to the treatment of chronic steroid-refractory gfart-versus-host disease // Blood reviews 2024; Vol. 63. P.101142.
  451. Schoemans H.M., Lee S.J., Ferrara J.L., et al. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment // Bone marrow transplantation 2018; Vol. 53, № 11. P. 1401–1415.
  452. Couriel D., Carpenter P.A., Cutler C., et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report // Biology of Blood and Marrow Transplantation 2006; Vol. 12, № 4. P. 375–396.
  453. Shekhovtsova Z., Shelikhova L., Balashov D., et al. Control of graft-versus-host disease with rabbit anti-thymocyte globulin, rituximab, and bortezomib in TCRαβ/CD19-depleted graft transplantation for leukemia in children: a single-center retrospective analysis of two GVHD-prophylaxis regimens // Pediatric Transplantation 2020; Vol. 24, № 1. P. e13594
  454. Kim B.K., Kang H.J., Hong K.T., et al. Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation // Transplant Infectious Disease 2019; Vol. 21, № 6. P. e13182.
  455. Albert M.H., Sirin M., Hoenig M., et al. Salvage HLA-haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for graft failure in non-malignant disorders // Bone Marrow Transplantation 2021; Vol. 56, № 9. P. 2248–2258
  456. Mikulska M. Infection Control and Isolation Procedures // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 189–197.
  457. Mikulska M. Neutropenic Fever // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 259–265.
  458. Ljungman P., Styczynski J., Einsele H. Viral Infections // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 281–291.
  459. Polomeni A., Moreno E., Schulz-Kindermann F. Psychological Morbidity and Support. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies [Internet]. 7th ed. Cham (CH): Springer; 2019. Chapter 30.
  460. Ljungman P., de la Camara R., Robin C., et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7) // The Lancet Infectious Diseases 2019; Vol. 19, № 8. P. e260–e272.
  461. Winston D.J., Yeager A.M., Chandrasekar P.H., et al. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation // Clinical Infectious Diseases 2003; Vol. 36, № 6. P. 749–758.
  462. Zaia J., Baden L., Boeckh M.J., et al. Viral disease prevention after hematopoietic cell transplantation // Bone Marrow Transplantation 2009; Vol. 44, № 8. P. 471–482.
  463. Кожушная О.С., Солопова Г.Г., Маркелов М.И, и др. Мониторинг мутаций в гене UL97 цитомегаловируса, ассоциированных с резистентностью к ганцикловиру, у детей после аллогенной трансплантации гемопоэтических стволовых клеток // Клиническая микробиология и антимикробная химиотерапия 2022; Том 24, № 1. стр. 47–51.
  464. Platzbecker U., Bandt D., Thiede C., et al. Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation // Transplantation 2001; Vol. 71, № 7. P. 880–885.
  465. Cesaro S., Zhou X., Manzardo C., et al. Cidofovir for cytomegalovirus reactivation in pediatric patients after hematopoietic stem cell transplantation // Journal of Clinical Virology 2005; Vol. 34, № 2. P. 129–132.
  466. Sanford Guide to Antimicrobial Therapy 2024, 54th edition (Spiral Edition). Eds.: Gilbert D.N., Chambers H.F., Saag M.S., et al. Antimicrobial Therapy Inc., 2024
  467. Maertens J.A. Invasive Fungal Infections // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 273–281.
  468. Groll A.H., Pana D., Lanternier F., et al. 8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation // The Lancet Oncology 2021; Vol. 22, № 6. P. e254–e269.
  469. Decembrino N., Perruccio K., Zecca M.,et al. A Case Series and Literature Review of Isavuconazole Use in Pediatric Patients with Hemato-oncologic Diseases and Hematopoietic Stem Cell Transplantation // Antimicrobial Agents and Chemotherapy 2020; Vol. 64, № 3. P. e01783–e01819
  470. Солопова Г.Г., Масчан А.А., Новичкова Г.А. Рекомендации 2020 года по диагностике и терапии инвазивного аспергиллеза у детей с онкогематологическими заболеваниями // Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2020; Том 19, № 1. стр. 158–166
  471. Cesaro S. Haemorrhagic Cystitis and Renal Dysfunction // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 387–393.
  472. Carreras E., Diaz-Ricart M. Early Complications of Endothelial Origin // EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 315–323.
  473. Mahadeo K.M., Bajwa R., Abdel-Azim H., et al. Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement // The Lancet Haematology 2020; Vol. 7, № 1. P. e61–e72.
  474. Carreras E., Dufour C., Mohty M., Kröger N., editors. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies [Internet]. 7th ed. Cham (CH): Springer; 2019
  475. Dignan F.L., Wynn R.F., Hadzic N., et al. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation // British Journal of Haematology 2013; Vol. 163, № 4. P. 444–457.
  476. Sung L., Robinson P., Treister N., et al. Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation // BMJ Supportive and Palliative Care 2017; Vol. 7, № 1. P. 7–16.
  477. Ghali M.G.Z., Davanzo J., Leo M., et al. Posterior reversible encephalopathy syndrome in pediatric patients: pathophysiology, diagnosis, and management // Leukemia & Lymphoma 2019; Vol. 60, № 10. P. 2365–2372.
  478. Cooke K.R. Acute lung injury after allogeneic stem cell transplantation: From the clinic, to the bench and back again // Pediatric Transplantation 2005; Vol. 9, Suppl. 7. P. 25–36.
  479. Jodele S., Dandoy C.E., Myers K.C., et al. New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy // Transfusion and Apheresis Science 2016; Vol. 54, № 2. P. 181–190.
  480. Khaled S.K., Claes K., Goh Y.T., et al. Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy // Journal of Clinical Oncology 2022; Vol. 40, № 22. P. 2447–2457.
  481. Yeates L., Slatter M.A., Bonanomi S., et al. Use of defibrotide to treat transplant-associated thrombotic microangiopathy: a retrospective study of the Paediatric Diseases and Inborn Errors Working Parties of the European Society of Blood and Marrow Transplantation // Bone Marrow Transplantation 2017; Vol. 52, № 5. P. 762–764.
  482. Uderzo C.C., Jodele S., Missiry M.E., et al. Transplant- associated thrombotic microangiopathy (TATMA) and consensus based diagnostic and therapeutic recommendations: which TA-TMA patients to treat and when? // Journal Of Bone Marrow Research 2014; Vol. 2. P. 152–159.
  483. Hayden P.J., Roddie C., Bader P., et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA) // Annals of Oncology 2022; Vol. 33, № 3. P. 259–275.
  484. Baumgartner A., Schuetz P. Nutritional Support // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 171–177.
  485. Schrezenmeier H. et al. Transfusion Support // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 163–171.
  486. Bahar B., Tormey C.A. Prevention of transfusion-associated graft-versus-host disease with blood product irradiation the past, present, and future // Archives of Pathology and Laboratory Medicine 2018; Vol. 142, № 5. P. 662–667.
  487. Bresters D., Lawitschka A., Cugno C., et al. Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really matters // Bone Marrow Transplantation 2016; Vol. 51, № 11. P. 1482–1489.
  488. Mulcahy Levy J.M., Tello T., Giller R., et al. Late effects of total body irradiation and hematopoietic stem cell transplant in children under 3 years of age // Pediatric Blood & Cancer 2013; Vol. 60, № 4. P. 700–704.
  489. Vrooman L.M., Millard H.R., Brazauskas R., et al. Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age // Biology of Blood and Marrow Transplantation 2017; Vol. 23, № 8. 1327–1334.
  490. Perkins J.L., Kunin-Batson A.S., Youngren N.M., et al. Long-term follow-up of children who underwent hematopoeitic cell transplant (HCT) for AML or ALL at less than 3 years of age // Pediatric Blood & Cancer 2007; Vol. 49, № 7. P. 958–963.
  491. Kobyzeva D., Shelikhova L., Loginova A., et al. Optimized Conformal Total Body Irradiation Among Recipients of TCRαβ/CD19-Depleted Grafts in Pediatric Patients With Hematologic Malignancies: Single-Center Experience // Frontiers in Oncology 2021; Vol. 11. P. 785916.
  492. Mohty M., Malard F., Abecassis M., et al. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT) // Bone Marrow Transplantation 2015; Vol. 50, № 6. P. 781–789.
  493. Cellini M., Bergadano A., Crocoli A., et al. Guidelines of the Italian Association of Pediatric Hematology and Oncology for the management of the central venous access devices in pediatric patients with onco-hematological disease // The Journal of Vascular Access 2022; Vol. 23, № 1. P. 3–17.
  494. Schiffer C.A., Mangu P.B., Wade J.C., et al. Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline // Journal of Clinical Oncology 2013; Vol. 31, № 10. P. 1357–1370.
  495. Лахин Р. Е., Заболотский Д. В., Теплых Б. А. Клинические рекомендации ФАР. Катетеризация сосудов под контролем ультразвука, 2015
  496. Bonciarelli G., Batacchi S., Biffi R., et al. GAVeCeLT* consensus statement on the correct use of totally implantable venous access devices for diagnostic radiology procedures // The Journal of Vascular Access 2011; Vol. 12, № 4. P. 292–305.
  497. Burbridge B., Plewes C., Stoneham G., et al. Randomized Clinical Trial Evaluating Complications and Complication-Related Removal of Arm-Situated Power-Injectable and Non-Power-Injectable Totally Implanted Venous Access Devices among Cancer Patients // Journal of Vascular and Interventional Radiology 2018; Vol. 29, № 5. P. 648–656.
  498. Skinner R, Koller K, McIntosh N, et al. Prevention and management of central venous catheter occlusion and thrombosis in children with cancer. Pediatr Blood Cancer 2008;50(4):826-30.
  499. Thurman C.B., Abbott M., Liu J., Larson E. Risk for Health Care-Associated Bloodstream Infections in Pediatric Oncology Patients With Various Malignancies // Journal of Pediatric Hematology/Oncology Nursing 2017; Vol. 34, № 3. P. 196–202.
  500. Cameron GS. Central venous catheters for children with malignant disease: surgical issues // Journal of Pediatric Surgery 1987; Vol. 22, № 8. P. 702–704.
  501. Pittiruti M., Annetta M.G., Marche B., et al. Ten years of clinical experience with cyanoacrylate glue for venous access in a 1300-bed university hospital // British Journal of Nursing 2022; Vol. 31, № 8. P. S4–S13.
  502. Di Puccio F., Giacomarro D., Mattei L., et al. Experimental study on the chemico-physical interaction between a two-component cyanoacrylate glue and the material of PICCs // The Journal of Vascular Access 2018; Vol. 19, № 1. P. 58–62.
  503. Nickel B., Gorski L., Kleidon T., et al. Infusion Therapy Standards of Practice, 9th Edition. Journal of Infusion Nursing 2024; Vol. 47, 1S Suppl 1. P. S1–S285.
  504. Pittiruti M., Van Boxtel T., Scoppettuolo G., et al. European recommendations on the proper indication and use of peripheral venous access devices (the ERPIUP consensus): A WoCoVA project //. Journal of Vascular Access 2023; Vol. 24, № 1. P. 165–182.
  505. Mehta N.M., Corkins M.R., Lyman B., et al. Defining pediatric malnutrition: a paradigm shift toward etiology-related definitions // Journal of Parenteral and Enteral Nutrition 2013; Vol. 37, № 4. P. 460–481.
  506. Jang R.W., Caraiscos V.B., Swami N., et al. Simple prognostic model for patients with advanced cancer based on performance status // Journal of Oncology Practice 2014; Vol. 10, № 5. P. e335–e341.
  507. Martin L., Senesse P., Gioulbasanis I., et al. Diagnostic criteria for the classification of cancer-associated weight loss // Journal of Clinical Oncology 2015; Vol. 33, № 1. P. 90–99.
  508. Kondrup J., Allison S.P., Elia M., et al. ESPEN guidelines for nutrition screening 2002 // Clinical Nutrition 2003; Vol. 22, № 4. P. 415–421.
  509. Arends J., Bachmann P., Baracos V., et al. ESPEN guidelines on nutrition in cancer patients // Clinical Nutrition 2017; Vol. 36, № 1. P. 11–48.
  510. Вашура АЮ, Кучер МА, Ковтун ТА, и др. Роль и актуальность нутрициологического диагноза в онкопедиатрии. Медицинский Совет 2023;(12):99-109.
  511. Yaprak D.S., Yalçın B., Pınar A.A., Büyükpamukçu M. Assessment of nutritional status in children with cancer: Significance of arm anthropometry and serum visceral proteins // Pediatric Blood & Cancer 2021; Vol. 68, № 1. P. e28752.
  512. Rayar M., Webber C.E., Nayiager T., et al. Sarcopenia in children with acute lymphoblastic leukemia // Journal of Pediatric Hematology/Oncology 2013; Vol. 35, № 2. P. 98–102.
  513. Pietilä S., Mäkipernaa A., Sievänen H., et al. Obesity and metabolic changes are common in young childhood brain tumor survivor // Pediatric Blood & Cancer 2009; Vol. 52, № 7. P. 853–859.
  514. Joosten K.F., Kerklaan D., Verbruggen S.C. Nutritional support and the role of the stress response in critically ill children // Current Opinion in Clinical Nutrition & Metabolic Care 2016; Vol. 19, № 3. P. 226–233.
  515. Elia M., Normand C., Laviano A., Norman K. A systematic review of the cost and cost effectiveness of using standard oral nutritional supplements in community and care home settings // Clinical Nutrition 2016; Vol. 35, № 1. P. 125–137.
  516. Langius J.A., Zandbergen M.C., Eerenstein S.E., et al. Effect of nutritional interventions on nutritional status, quality of life and mortality in patients with head and neck cancer receiving (chemo)radiotherapy: a systematic review // Clinical Nutrition 2013; Vol. 32, № 5. P. 671–678.
  517. Corry J., Poon W., McPhee N., et al. Randomized study of percutaneous endoscopic gastrostomy versus nasogastric tubes for enteral feeding in head and neck cancer patients treated with (chemo)radiation // Journal of Medical Imaging and Radiation Oncology 2008; Vol. 52, № 5. P. 503–510.
  518. Парентеральное и энтеральное питание детей. Практические рекомендации. Под ред. Ерпулевой Ю.В., Чубаровой А.И., Чугуновой Ю.Л. ГЭОТАР-Медиа, 2016, 304 с.
  519. ESPEN Guidelines on Enteral Nutrition // Clinical Nutrition 2006; Vol. 25. P. 177–360.
  520. Viani K., Trehan A., Manzoli B., Schoeman J. Assessment of nutritional status in children with cancer: A narrative review // Pediatric Blood & Cancer 2020; Vol. 67, Suppl 3. P. e28211.
  521. Hesketh P.J., Kris M.G., Basch E., et al. Antiemetics: ASCO Guideline Updat // Journal of Clinical Oncology 2020; Vol. 38, № 24. P. 2782–2797.
  522. Naik R.D., V S., Singh V., et al. Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy: Investigator-Initiated, Randomized, Open-Label Trial // Journal of Clinical Oncology 2020; Vol. 38, № 32. P. 3785–3793.
  523. Жуков Н.В., Рабаева Л.Л., Литвинов Д.В. Эффективность и безопасность малых доз оланзапина в профилактике тошноты и рвоты у детей и подростков, получающих высокоэметогенную химиотерапию. Промежуточные результаты рандомизированного исследования // Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2022; Том 21, № 4. стр. 70–82.
  524. Mohammed O., Thota N.K. Efficacy, safety and cost effectiveness of reduced-dose olanzapine versus aprepitant as a part of triple-antiemetic therapy in the prevention of chemotherapy induced nausea and vomiting // Journal of Clinical Oncology 2022; Vol. 40, 16 Suppl. P. e24078.
  525. Navari R.M., Le-Rademacher J., Smieliauskas F., et al. Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602) // Journal of Clinical Oncology 2022; Vol. 40, 16 Suppl. P. e12107.
  526. Patil V., Prasada H., Prasad K., Shenoy U.V. Comparison of antiemetic efficacy and safety of palonosetron vs ondansetron in the prevention of chemotherapy-induced nausea and vomiting in children // Journal of Community and Supportive Oncology 2015; Vol. 13, № 6. P. 209–213.
  527. Chaudhary N.K., John R.R., Boddu D., et al. Palonosetron is a Better Choice Compared With Ondansetron for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in a Resource-limited Pediatric Oncology Center: Results From a Randomized Control Trial // Journal of Pediatric Hematology/Oncology 2019; Vol. 41, № 4. P. 294–297.
  528. Flank J., Robinson P.D., Holdsworth M., et al. Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-Induced Nausea and Vomiting in Children With Cancer // Pediatric Blood & Cancer 2016; Vol. 63, № 7. P. 1144–1151.
  529. Patel P., Robinson P.D., Thackray J., et al. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update // Pediatric Blood & Cancer 2017; Vol. 64, № 10.
  530. Patel P., Olteanu A., Cabral S., et al. Dexamethasone dosing for prevention of acute chemotherapy-induced vomiting in pediatric patients: A systematic review // Pediatric Blood & Cancer 2020; Vol. 67, №12. P. e28716
  531. Bercovitz R.S., Josephson C.D. Transfusion Considerations in Pediatric Hematology and Oncology Patients // Hematology/Oncology Clinics of North America 2016; Vol. 30, № 3. P. 695–709.
  532. Steiner M.E., Zantek N.D., Stanworth S.J., et al. Recommendations on RBC transfusion support in children with hematologic and oncologic diagnoses from the pediatric critical care transfusion and anemia expertise initiative // Pediatric Critical Care Medicine 2018. Vol. 19, № 9. P. S149–S156.
  533. Shah N., Andrews J., Goodnough L.T. Transfusions for anemia in adult and pediatric patients with malignancies // Blood Reviews 2015; Vol. 29, № 5. P. 291–299.
  534. World Health Organization. Educational modules on clinical use of blood. 2021. P. 183.
  535. Долгов В.В., Вавилова Т.В., Свирин П.В. Лабораторная диагностика нарушений гемостаза. Триада, 2019, 400 с.
  536. Кречетова А.В. Нарушение гемостаза при сепсисе у онкогематологических больных c миелотоксическим агранулоцитозом: автореферат диссертации кандидата медицинских наук. М.: Гематологический научный центр, 2011, 25 с.
  537. Kozek-Langenecker S.A., Ahmed A.B., Afshari A., et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: First update 2016 // European Journal of Anaesthesiology 2017; Vol. 34, № 6. P. 332–395.
  538. O'Shaughnessy D.F., Atterbury C., Bolton Maggs P., et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant // British Journal of Haematology 2004; Vol. 126, № 1. P. 11–28.
  539. Галстян Г.М., Гапонова Т.В., Жибурт Е.Б., и др. Клиническое использование криопреципитата // Гематология и трансфузилогия 2020; Том 65, № 1. стр. 87–114.
  540. Darmon M., Guichard I., Vincent F., et al. Prognostic significance of acute renal injury in acute tumor lysis syndrome // Leukemia & Lymphoma 2010; Vol. 51, № 2. P. 221–227.
  541. Weeks A.C., Kimple M.E. Spontaneous Tumor Lysis Syndrome: A Case Report and Critical Evaluation of Current Diagnostic Criteria and Optimal Treatment Regimens // Journal of Investigative Medicine High Impact Case Reports 2015; Vol. 3, № 3.
  542. Faheem B., Kollimuttathuillam S., Ashkar H., Maroules M. Spontaneous Tumor Lysis Syndrome in T-Cell Leukemia // Cureus 2020; Vol. 12, № 10. P. e11002.
  543. Hsu H.H., Chan Y.L., Huang C.C. Acute spontaneous tumor lysis presenting with hyperuricemic acute renal failure: clinical features and therapeutic approach // Journal of Nephrology 2004; Vol. 17, № 1. P. 50–56.
  544. Cairo M.S., Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification // British Journal of Haematology 2004; Vol. 127, № 1. P. 3–11.
  545. Howard S.C., Jones D.P., Pui C.H. The tumor lysis syndrome // The New England Journal of Medicine 2011; Vol. 364, № 19. P. 1844–1854.
  546. Tosi P., Barosi G., Lazzaro C., et al. Consensus conference on the management of tumor lysis syndrome // Haematologica 2008; Vol. 93, № 12. P. 1877–1885.
  547. Williams S.M., Killeen A.A. Tumor Lysis Syndrome // Archives of Pathology & Laboratory Medicine 2019; Vol. 143, № 3. P. 386–393.
  548. Martin A., Acierno M.J. Continuous renal replacement therapy in the treatment of acute kidney injury and electrolyte disturbances associated with acute tumor lysis syndrome // Journal of Internal Medicine 2010; Vol. 24, № 4. P. 986–989.
  549. Rampello E., Fricia T., Malaguarnera M. The management of tumor lysis syndrome // Nature Clinical Practice Oncology 2006; Vol. 3, № 8. P. 438–447.
  550. Новичкова Г.А., Птушкин В.В., Румянцев А.Г. Клинические рекомендации по профилактике и лечению синдрома лизиса опухоли у детей и подростков // Российский журнал детской гематологии и онкологии (РЖДГиО) 2014; Том 1, № 1. стр. 37–50
  551. Schwartz W.B., Bennett W., Curelop S., Bartter F.C. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone // The American Journal of Medicine 1957; Vol. 23, № 4. P. 529–542.
  552. Verbalis J.G., Goldsmith S.R., Greenberg A., et al. Hyponatremia treatment guidelines 2007: expert panel recommendations // The American Journal of Medicine 2007; Vol. 120, Suppl 1. P. S1–S21.
  553. Spasovski G., Vanholder R., Allolio B., et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia // European Journal of Endocrinology 2014; Vol. 170, № 3. P. G1–G47.
  554. Garrahy A., Dineen R., Hannon A.M., et al. Continuous Versus Bolus Infusion of Hypertonic Saline in the Treatment of Symptomatic Hyponatremia Caused by SIAD // The Journal of Clinical Endocrinology & Metabolism 2019; Vol. 104, № 9. P. 3595–3602.
  555. Alenazi A.O., Alhalimi Z.M., Almatar M.H., Alhajji T.A. Safety of Peripheral Administration of 3% Hypertonic Saline in Critically Ill Patients: A Literature Review // Critical Care Nurse 2021; Vol. 41, № 1. P. 25–30.
  556. Paediatric Intensive Care. Edited by Peter Barry, Kevin Morris, and Tariq Ali, 2010, 896 р.
  557. Shelikhova L., Ilushina M., Shekhovtsova Z., et al. αβ T Cell-Depleted Haploidentical Hematopoietic Stem Cell Transplantation without Antithymocyte Globulin in Children with Chemorefractory Acute Myelogenous Leukemia // Biology of Blood and Marrow Transplantation 2019; Vol. 25, № 5. P. e179–e182.
  558. Maschan M., Shelikhova L., Ilushina M., et al. Outcome of αβ T cell-depleted transplantation in children with high-risk acute myeloid leukemia, grafted in remission // Bone Marrow Transplantation 2020; Vol. 55, № 1. P. 256–259.
  559. . Karakaş Z., Koç B.S., Karaman S., et al. Clofarabine experience in children with multi-relapsed acute leukemia // Turkish Journal of Hematology 2014; Vol. 31, № 3. P. 323–324.
  560. Militano O., Ozkaynak M.F., Mehta B., et al. Mycophenolate mofetil administered every 8 hours in combination with tacrolimus is efficacious in the prophylaxis of acute graft versus host disease in childhood, adolescent, and young adult allogeneic stem cell transplantation recipients // Pediatric Blood & Cancer 2018; Vol. 65, № 8. P. e27091.
  561. Pulsipher M.A., Langholz B., Wall D.A., et al. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial // Blood 2014; Vol. 123, № 13. P. 2017–2025.
  562. Pulsipher M.A., Wall D.A., Grimley M., et al. A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL) // British Journal of Haematology 2009; Vol. 147, № 5. P. 691–699.
  563. Abdalla S., Briand C., Oualha M., et al. Population Pharmacokinetics of Intravenous and Oral Acyclovir and Oral Valacyclovir in Pediatric Population to Optimize Dosing Regimens // Antimicrobial Agents and Chemotherapy 2020; Vol. 64, № 12. P. e01426
  564. Nguyen T., Oualha M., Briand C., et al. Population Pharmacokinetics Ganciclovir and Oral Valganciclovir in a Pediatric Population To Optimize Dosing Regimens // Antimicrobial Agents and Chemotherapy 2021; Vol. 65, № 3. P.e02254.
  565. Alcamo A.M., Wolf M.S., Alessi L.J., et al. Successful Use of Cidofovir in an Immunocompetent Child With Severe Adenoviril Sepsis // Pediatrics 2020; Vol. 145, № 1. P. e20191632
  566. Marjanska A., Pogorzała M., Dziedzic M., et al. Impact of prophylaxis with rituximab on EBV-related complications after allogenic hematopoietic cell transplantation in children. Frontiers in Immunology 2024; Vol. 15. P. 1427637
  567. Xie R., McFadyen L., Raber S., et al. Population Analysis of Anidulafungin in Infants to Older Adults With Confirmed or Suspected Invasive Candidiasis // Clinical Pharmacology & Therapeutics 2020; Vol. 108, № 2. P. 316–325

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*